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Sthaphylococcus pseudintermedius (S. pseudintermedius) is the main 
inhabitant of skin and mucosa of dogs, where it represents the major 
bacterial pathogen causing skin diseases.  
Firstly described in 2005, S. pseudintermedius is a member of the 
Staphylococcus intermedius Group (SIG), together with S. intermedius 
and S. delphini.   
The recent emergence and rapid dissemination of multidrug-resistant S. 
pseudintermedius strains, particulary methicillin-resistant S. 
pseudintermedius (MRSP), showing more and more often resistance to 
the antibiotic agents licensed for use in small animal practice, represent a 
relevant threat to small animal and public health. In the last decade, the 
antibiotic resistance issue has become increasingly relevant, highlighting 
the need to control and limit it by the means of a continuous surveillance 
of both methicillin-resistant and methicillin-susceptible S. 
pseudintermedius isolates as well as the development of new and 
alternative therapeutic options.  
This study aims to describe the phenotypic and genotypic features, the 
antibiotic resistance patterns, the prevalence of virulence genes of both 
MRSP and methicillin-susceptible S. pseudintermedius (MSSP) strains, 
isolated from dogs suffering from otitis externa and pyoderma. MRSP 
sequence type clones circulating in Southern Italy were also investigated.  
Moreover, the antimicrobial activity of hydroxypiridone-based iron 
chelating co-polymer DIBI and abietic acid was analyzed against S. 
pseudintermedius isolates, as alternative treatment options.  
From a total of 259 staphylococcal cultures, 126 S. pseudintermedius 
strains were selected during the years 2015-2017.  
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S. pseudintermedius strains (49%) were identified by proteomic (MALDI-
TOF MS) and molecular profiling (nuc and hlb genes). S. 
pseudintermedius strains were recovered from dogs suffering from otitis 
externa (84%) and pyoderma (16%), originating from Naples, Campania 
Region (52%) and Latina, Lazio Region (48%).  
Amongst the 126 S. pseudintermedius strains, 18% were MRSP, carrying 
mecA gene. The remaining 82% were classified as MSSP. None of the 
isolates was positive to mecC gene.  
 Furthermore, all the MRSP showed a complete resistance to amoxicillin-
clavulanate and ampicillin (100%), while the highest resistance rates to 
selected non-β-lactam antibiotics were registered for erythromycin (91%); 
tetracycline (87%); sulfamethoxazole/trimethoprim (78%); kanamycin 
(78%); streptomycin (78%); clindamycin (65%) and enrofloxacin (61%). 
However, there was no resistance to vancomycin and linezolid.  It is 
worth noting that 91% MRSP strains were found to be multidrug-resistant 
strains. The 82% MSSP isolates, showed interesting antibiotic resistant 
profiles, but their resistance rates were of about 50% lower than MRSP 
strains. 
The phenotypic tetracycline- and erythromycin-resistant MRSP and 
MSSP strains harbored tetK and tetM genes, alone or in association, and 
ermB gene.   
Referring to MRSP isolates, they mainly belonged to multidrug-resistant 
sequence type ST71 (26%) European clone. In this study, 9 new clones of 
MRSP were identified and described in Italy and worldwide for the first 
time. The newly described sequence types (STs) were named from 
ST1053 up to ST1061. 
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In addition, DIBI and abietic acid resulted to be effective against MRSP 
and MSSP strains, inhibiting their growth. Thus, they may be considered 
as valid non-antibiotic alternative treatment approaches for S. 
pseudintermedius infections.  
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The bacterial genus of Staphylococcus consists of many species that are 
part of the natural microbiota of humans and animals.  
Staphylococcus intermedius, Staphylococcus pseudintermedius, and 
Staphylococcus delphini together compose the Staphylococcus intermedius 
Group (SIG). In particular, Staphylococcus pseudintermedius is the most 
common coagulase-positive staphylococcus isolated from dogs, in which 
this opportunistic Gram-positive bacterium can be responsible for a great 
variety of infections including pyoderma, otitis, abscesses, urinary tract 
infections (UTIs) and wound infections (Weese and van Duijkeren, 2010; 
Rubin et al., 2011; Youn et al., 2014). 
Over the last decade, S. pseudintermedius has become a critically 
opportunistic small animal pathogen, being frequently the primary 
aetiological agent of pyoderma and otitis (De Martino et al., 2016; 
Loeffler and Lloyd, 2018). Even though dog is its natural host, human 
carriage and infections have been reported, highlighting the potential 
zoonotic transmission of this species (Somayaji et al., 2016).  
Since its first description as a novel coagulase-positive staphylococcal 
species in 2005, the phenotypic identification of S. pseudintermedius has 
persisted problematic. Commercial kits, commonly used in routine 
laboratory diagnostics, are not able to identify and distinguish S. 
pseudintermedius from the other members of the SIG and from S. aureus, 
because of their similar phenotypic characters. Moreover, as coagulase-
negative Staphylococci (CoNS) also S. pseudintermedius generally gives 
negative results to rapid slide clumping and commercial latex 
agglutination tests. For these reasons, the real prevalence of S. 
pseudintermedius might have been underestimated in clinical 
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microbiology laboratories (Weese and van Duijkeren, 2010). So, 
molecular profiling continues to represent a necessary tool for a proper 
determination and diagnosis of S. pseudintermedius. However, 
Decristophoris et al. (2011), reported that MALDI-TOF MS, provided 
with a reliable database, is an effective technique for a rapid identification 
of S. pseudintermedius and the other two bacterial species of the SIG. 
Antibiotic resistance is the most puzzling question of public health of the 
earlier decade of this 21st century and already since 2006 methicillin-
resistant S. pseudintermedius (MRSP) strains have been identified, which 
have been also proved to be multidrug-resistant displaying resistance to 
most of the antibiotics approved for use in pet animals (Kadlec and 
Schwarz, 2012; Moodley et al., 2014).  
This high prevalence of multidrug-resistant strains seems to be related to 
the dissemination of dominant clones, such as MRSP belonging to the 
clonal lineage ST71. ST71 is a widespread clone, being isolated across the 
European, American and Asiatic continents.  As reported by Perreten at al. 
(2010) in their multicenter study, a high percentage of MRSP ST71 were 
resistant to at least six antimicrobial classes. Furthermore, new  multidrug 
MRSP clones are constantly reported worldwide.  
Therefore, the increasing spread of multidrug-resistant strains represents 
an important threat for animal and public health, since dogs, and in general 
pet animals, represent potential sources of spread of antimicrobial 
resistance due to the extensive use of antimicrobial agents; this spread 
may concern also humans, because of their close contact with pets. Thus, 
it is not only of veterinary significance, but has a zoonotic importance, 
with pets acting as reservoirs for humans, particularly pet owners and 
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veterinarians. Moreover, the lack of effective antimicrobial therapeutic 
treatments underlines the need of new alternative approaches to prevent 
and limit the dissemination of multidrug resistant bacterial isolates.  
 
The purpose of this PhD thesis was to investigate the phenotypic and 
genotypic antibiotic resistance patterns of clinical methicillin-resistant and 
methicillin-susceptible Staphylococcus pseudintermedius strains 
associated with the most common clinical cases of otitis externa and 
pyoderma in dogs, attending the Veterinary Teaching Hospital (OVUD) of 
the Department of Veterinary Medicine and Animal Production, 
University of Naples “Federico II” and the Provet Lab srl of Latina. The 
dominant MRSP clones circulating in Southern Italy were also 
investigated. Furthermore, the antimicrobial activity against S. 
pseudintermedius of the two non-antibiotic agents DIBI (Chelation 
Parteners Inc. proprietary) and abietic acid was analyzed as alternative 
therapeutic options.    
 
The topics of the thesis are organized in four chapter as follows. 
Chapter 1 is focused on the: 
- isolation and collection of S. pseudintermedius strains obtained from 
swabs of dogs suffering from otitis externa and pyoderma; 
- comparison of Api Staph conventional biochemical test, matrix- assisted 
laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF MS) system and polymerase chain reaction (PCR) for the S. 
pseudintermedius identification.   
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Chapter 2 is focused on the: 
- discrimination of methicillin-resistant S. pseudintermedius (MRSP) from 
methicillin-susceptible S. pseudintermedius (MSSP) isolated strains by 
PCR for mecA and mecC genes; 
- evaluation of the antibiotic resistance profile to a panel of 20 
antimicrobial agents by the disk diffusion method on Mueller-Hinton agar 
plates (Liofilchem, Teramo, Italy), according to the guidelines of the 
Clinical Laboratory Standard Institute (CLSI, 2015); 
- determination of the presence of the different tet and erm genes in 
tetracycline- and erythromycin-resistant strains by PCR.  
 
In Chapter 3, multilocus sequence typing (MLST) was performed to 
investigate the MRSP sequence type clones circulating in Southern Italy 
and to correlate their antibiotic resistance patterns to the belonging clones.  
 
The aim of Chapter 4 was to investigate new therapeutic options, in order 
to prevent the spread of antibiotic resistance, since it is one of the most 
urgent threat to the public’s health.  So, the antimicrobial properties of 
DIBI, a novel iron chelating polymer developed by Chelation Partners Inc. 
(Canada), and abietic acid against MRSP and MSSP strains were tested.  
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Chapter 1 
Bacterial skin disorders in dogs 
Staphylococcus pseudintermedius as main bacterial agent of canine otitis 
and pyoderma 
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1. Introduction 
 
Canine bacterial skin infections represent the mainly reason of 
presentation in small animal practice and are generally secondary 
complications of a range of canine skin diseases including endocrine, 
allergic, seborrheic and follicular disorders (Miller et al., 2013). Indeed, 
many bacterial species, especially Staphylococci, are part of the natural 
skin microbiota but particular conditions such as flea infestation, 
allergic reaction, immune system depletion can lead to an excessive 
skin bacteria proliferation with the appearance of cutaneous infection 
symptoms. Infected dogs can show pruritus, areas of redness, rash-like 
pustules and hair loss.  
In dogs, skin and ear infections are very commonly caused by 
Staphylococcus pseudintermedius (S. pseudintermedius) since it is a 
normal inhabitant of the skin and mucosa of dogs and cats (Van 
Duijkeren et al., 2011). Thus, Staphylococcus pseudintermedius is an 
opportunistic pathogen and a leading cause of skin, ear and post-
operative wound infections in dogs and marginally in cats (Fitzgerald, 
2009; Weese and van Duijkeren, 2010). 
Canine otitis externa and pyoderma are featured consistently as the 
major diseases affecting canine skin system.  
 
 
• Canine otitis externa 
Otitis externa is the most common ear disease seen in dogs, affecting 
up to 20% of the canine population (De Martino et al., 2016). It has a 
multifactorial etiology and the otitis causes can be classified as 
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predisposing, primary and perpetuating factors. Moreover, the 
predisposing factors can be related to the host and to the environment 
(Fig 1.1).  
Among the predisposing factors related to the host, anatomical changes 
of the ear canal as conformational abnormalities linked to the belonging 
breed seem to be the main otitis causes. The most frequently affected 
breeds are: german shepherds for the high moisture levels in their ear 
canals, cocker spaniels for their pendulous pinnae, shar-peis for their 
hypoplastic and stenotic ear canals and poodles for a high density of 
hair in their ear canals (Zur et al., 2011). 
Another aspect to consider is represented by the habits of the animals, 
that is to say dogs living outdoor and hunting dogs have more 
possibilities to develop otitis externa because foreign fragment of 
twigs, plants or dirty materials can contaminate their ear canal. 
Moreover, dogs that are often washed or do swimming activities are 
predisposed to otitis for the excessive stimulations of the ceruminous 
glands. Consequently, the humidity in the ear canal compromise the 
protective function of the epidermidis. 
Some studies have shown that changes in temperature and humidity of 
the surrounding environment are related to temperature changes and 
dampness of the ear canal (Logas, 1994). 
The most common primary causes of otitis externa are allergies such as 
atopic dermatitis and adverse food reactions. Keratinization disorders, 
either primary (idiopathic seborrhea) or secondary as in hypothyroidism 
and sex hormone imbalance, are also common primary causes affecting 
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the secretions of the ceruminous and sebaceous glands lining the ear 
canal (Rosser, 2004). 
The predisposing factors and primary causes create suitable conditions 
for the growth and the proliferation in the ear canal of microorganisms 
such as bacteria and yeast, that represent both predisposing and 
perpetuating factors. Many studies report that the most common 
bacterial pathogens isolated from canine otitis externa are 
Staphylococcus pseudintermedius, Pseudomonas aeruginosa, Proteus 
mirabilis, Streptococcus spp. and Escherichia coli (Hariharan et al. 
2000; Lyskova et al., 2007). Whilst among yeasts, Malassezia 
pachydermatis has been reported as the major causative agent of canine 
otitis externa (De Martino et al., 2016). 
 
 
 
                                                               
Fig. 1.1 Canine otitis externa  
 
• Canine pyoderma 
Pyoderma refers to a bacterial skin disorder and it comes from Greek 
words pyo meaning “pus” and derma meaning “skin. Pyoderma is 
common in dogs and less common in cats and it is one of the main 
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presentations leading to antimicrobial prescription in small animal 
practice (Hughes et al., 2012). Bacterial pyoderma is usually triggered 
by an overgrowth/overcolonization of normal resident or transient flora. 
Since Staphylococcus pseudintermedius is a normal commensal of dog, 
it is the most commonly pathogen of canine pyoderma, in particular 
superficial pyoderma.  However, normal resident bacteria in canine 
skin also include coagulase-negative staphylococci, streptococci, 
Micrococcus spp, and Acinetobacter spp. Transient bacteria in canine 
skin include Bacillus spp., Corynebacterium spp., Escherichia coli, 
Proteus mirabilis, and Pseudomonas spp. These organisms may play a 
role as secondary pathogens, but often S. pseudintermedius is required 
for a pathologic process to ensue. 
Bacterial pyoderma can occur either as simple infection or complex 
infection. Simple infections are those occurring in young animals that 
are triggered by one-time or simple events, such as flea infestation. 
Complex infections are recurrent and are associated with underlying 
diseases, such as allergies, endocrinopathies, seborrheic conditions, 
parasitic diseases (Demodex canis), or anatomic predispositions. 
Regarding to the anatomic predisposition, it has been suggested that in 
dog pyoderma is partly a consequence of the thin and compact stratum 
corneum, of the paucity of intracellular emulsion in epidermidis and of 
the absence of a sebum plug in the hair follicle (Loeffler and Lloyd, 
2018).  
Bacterial pyoderma is generally classified as surface, superficial and 
deep pyoderma on the basis of the depth of infection. 
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Surface pyoderma remains the less known. It comprises acute moist 
dermatitis (hot spots, pyotraumatic dermatitis), fold pyoderma 
(intertrigo) and microbial/bacterial overgrowth syndrome, in which 
erythema is the only clinical sign.  
Superficial pyoderma, named also superficial bacterial folliculitis, is the 
most recurrent type of canine pyoderma (Fig.1.2). It is limited to the 
epidermis that is invaded by bacteria. The clinical signs are papules, 
pustules and epidermal collarettes, which are typically confined to the 
ventral abdomen, medial thighs and to the trunk. Moreover, it is often 
associated with alopecia and pruritus (Loeffler and Lloyd, 2018).  In 
fact, the most important factor in superficial pyoderma is the bacterial 
adherence, or “stickiness,” to the keratinocytes. Warm, moist areas on 
the skin, such as lip folds, facial folds, neck folds, dorsal or plantar 
interdigital areas, vulvar fold, sand tail folds, often have higher 
bacterial counts than other areas of skin and are at an increased risk of 
infection. Pressure points, such as elbows and hocks, are prone to 
infections, possibly because of follicular irritation and rupture due to 
chronic repeated pressure. Deep pyoderma is less frequent but more 
serious, since it involves the dermis (deep folliculitis and furunculosis, 
and cellulitis). Blood vessels may also be involved with a high risk of 
hematogenous spread and bacteremia. 
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Fig. 1.2 Canine superficial pyoderma (Foglia Manzillo et al., 2016) 
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1.1 Staphylococcus pseudintermedius: the main opportunistic dog 
pathogen.  
Staphylococcus intermedius was first described in 1976 and it has been 
considered as the major strain responsible of canine skin disorders for a 
long time (Hajek, 1976; Fitzgerald, 2009). However, the development 
of molecular techniques revealed a genetic diversity among S. 
intermedius isolates and in 2005 a novel staphylococcal species, 
Staphylococcus pseudintermedius, was defined based on the sequential 
analysis of 16S rRNA (Devriese et al., 2005). 
Therefore, the isolates, that previously could not be distinguished by 
biochemical and morphological characters, in 2007 were grouped in the 
Staphylococcus intermedius Group (SIG) and differentiated thanks to 
the sequential analysis of sodA and hsp60. Thus, SIG comprises three 
distinct species: Staphylococcus intermedius, Staphylococcus 
pseudintermedius and Staphylococcus delphini, each of which has 
different ecological niches (Bannoehr et al., 2007; Sasaki et al., 2007).   
Importantly, it was discovered that S. pseudintermedius, not S. 
intermedius, is a member of the normal skin canine microbiota and an 
opportunistic pathogen (Fig. 1.3). 
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Fig. 1.3 Staphylococcus pseudintermedius ecological niche 
(Bannoehr and Guardabassi, 2012) 
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Precisely, Staphylococcus pseudintermedius can be isolated from the 
nares, oral mucosa, pharynx, forehead, groin and anus of healthy dogs 
(Garbacz et al., 2013). So, it is the most common bacterial pathogen 
associated with canine infections, predominantly skin infections (Fig. 
1.4). 
 
 
 
          
 
 
Fig. 1.4 Staphylococcus pseudintermedius colonization in dog  
(Bannoehr and Guardabassi, 2012) 
 
 
 
Ben Zakour et al. (2011), reported the first whole-genome sequence of 
a canine clinical isolate of S. pseudintermedius (ED99). Its genome 
consisted of a single circular chromosome of 2,572,216 bp with an 
average G+C content of 37,6%, carried five ribosomal operons and 58 
tRNA loci and encoded for 2401 predicted proteins coding sequences 
(CDSs). Moreover, S. pseudintermedius ED99 contained many 
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predicted mobile genetic elements, including insertion elements, 
transposons mediating resistance to antibiotics, a novel member of the 
staphylococcal pathogenicity island family (SaPI). The genome of other 
isolated S. pseudintermedius strains has been also sequenced (Tse et al., 
2011; Moodley et al., 2013; Duim et al., 2018). As other 
staphylococcal species, also S. pseudintermedius has various virulence 
factors (Fig. 1.5), including some that are closely related to S. aureus 
(Fitzgerald, 2009; Bannoehr and Guardabassi, 2012). These factors of 
virulence take part in almost all processes from colonization of the host 
to bacterial nutrition and dissemination.  
S. pseudintermedius has the capability to produce some enzymes such 
as coagulase, protease, thermonuclease and toxins. Among toxins, 
mainly β-haemolysins (but some strains also α and ᵹ haemolysins), 
exfoliative toxins and enterotoxins are produced. Exfoliative toxin 
seems to be the factor involved in canine pyoderma, because the 
exfoliative toxin gene has been harbored in many S. pseudintermedius 
isolated from dogs suffering from skin infections, that is to say chronic 
otitis and pyoderma (Iyori et al., 2010). 
Furthermore, similarly to S. aureus, also S. pseudintermedius produces 
a leucotoxin and an immunoglobulin-binding protein, which are known 
as Luk-I and staphylococcal protein A (spa), respectively (Moodley et 
al., 2009). Genes encoding virulence factors are usually located on 
mobile genetic elements such as pathogenicity islands.  The production 
of virulence factors is regulated by several regulatory loci such as the 
accessory gene regulator (agr) and the staphylococcal accessory 
regulator (sar) in response to cell density, energy availability and 
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environmental signals. The accessory gene agr is a staphylococcal 
quorum-sensing system, which encodes the auto-inducing peptide 
(AIP). All staphylococcal species encode a unique to each species AIPs 
(Dufour et al., 2002). 
 
 
 
 
Fig. 1.5. S. pseudintermedius virulence armamentarium  
          (Bannoehr and Guardabassi, 2012) 
 
As other staphylococcal species, S. pseudintermedius strains can be 
biofilm producers, which represents another important virulence 
determinant, increasing their ability to resist to antibiotics (Casagrande 
Proietti et al., 2015; Han et al., 2015).  
The biofilm production by S. pseudintermedius, as well as S. aureus, 
may contribute to its ability to persist in the environment, cause 
nosocomial infections, and chronic recurrent infections that respond 
poorly to antimicrobial treatment. 
S. pseudintermedius as main agent of canine skin disorders   
 
46 
 
However, the knowledge on the pathogenesis of S. pseudintermedius is 
very limited, since the majority of virulence factors have not been 
characterized in detail yet. 
 
In the past, the S. pseudintermedius isolates were generally susceptible 
to β-lactams, whose major antimicrobial agent is penicillin, and many 
other antibiotics. Therefore, methicillin-susceptible S. 
pseudintermedius (MSSP) strains originally circulated in canine 
population.  However, already since 2006 methicillin-resistant S. 
pseudintermedius (MRSP) strains have been isolated in Europe, 
becoming a relevant problem in veterinary medicine. A veterinary 
health issue comparable to the public health concern due to methicillin-
resistant S. aureus (MRSA) (Deurenberg et al., 2007). 
Referring to S. pseudintermedius virulence potential, its zoonotic 
transmission should not be underestimated, even though it is not often 
reported. However, S. pseudintermedius, particularly MRSP, has been 
sometimes isolated from humans, especially in pet owners. It is worth 
noting that infections caused by S. pseudintermedius in humans are 
often underreported due to inaccurate identification as S. aureus (Van 
Hoovels et al., 2006; Stegmann et al., 2010; Somayaji et al., 2016; 
Robb et al., 2017; Lozano et al., 2017).    
 
1.2 Phenotypic features of Staphylococcus pseudintermedius 
Staphylococcus pseudintermedius comes from Greek words pseudes or 
pseudos meaning false and from intermedius meaning intermediate. 
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Thus, the adjective pseudintermedius indicates a false (Staphylococcus) 
intermedius, because of its high phenotypic similarity to S. intermedius.  
Indeed, S. pseudintermedius is a Gram-positive coccus arranged in 
groups as the other staphylococcal species (Fig. 1.6).  
During the diagnostic activity, the media used for growth and the 
isolation of S. pseudintermedius strains are different, but generally 
Columbia sheep blood agar is routinely used. Here colonies appear 
non-pigmented and always surrounded by double zone haemolysis. The 
outer band, which is incompletely haemolytic, becomes completely 
haemolytic after being put at 4°C (hot–cold haemolysis). This is due to 
the activity of the staphylococcal β-haemolysin, that is a 
sphingomyelinase (Devriese et al., 2005). Furthermore, also Mannitol 
Salt Agar (MSA) plates are used for the isolation of this strain. In 
particular, MSA was developed in 1945 for the selective isolation of 
pathogenic staphylococci. Since S. pseudintermedius is a mannitol 
negative strain, differently from S. aureus but similarly to coagulase-
negative staphylococci, its colonies on this medium appear light pink 
for the missing fermentation of mannitol sugar contained in MSA 
plates. This is one of the reasons for S. pseudintermedius was often 
misidentified as coagulase- negative staphylococcus. 
Together with the other members of the SIG, S. pseudintermedius is a 
coagulase-positive species (CoPS), producing the coagulase enzyme, 
which is a relevant virulence factor since it represents the way to evade 
the host immune system. Coagulase is an extracellular protein that 
binds the host prothrombin to form a complex called staphylothrombin 
(McAdow et al., 2012). The complex formation allows the conversion 
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of fibrinogen into fibrin (Władyka and Pustelny, 2008). Moreover, it is 
catalase positive and DNase positive, but it is normally negative to 
rapid slide clumping test and to commercial latex agglutination tests 
that detect the clumping factor. 
The identification of S. pseudintermedius is problematic. Phenotypic 
identification is defective and there are not commercial kits that can 
identify S. pseudintermedius and distinguish it from the other members 
of the SIG and from S. aureus, because they share many phenotypic 
characters. Since phenotypic discrimination of CoPS species is 
difficult, the real prevalence of S. pseudintermedius might have been 
underestimated being misidentified with other CoPS, especially S. 
intermedius or S. aureus, in routine laboratory diagnostics (Weese and 
van Duijkeren, 2010). 
Consequently, the molecular identification embodies the only reliable 
tool for a proper determination and diagnosis of S. pseudintermedius.  
 
 
Fig. 1.6 S. pseudintermedius: Gram stain 
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In fact, to distinguish the belonging species of the SIG, a species-
specific multiplex PCR based on the thermonuclease (nuc) gene is 
routinely performed as described by Sasaki et al. (2010).  S. 
pseudintermedius constitutively produces β-haemolysin. Kmieciak et 
al. (2016) have designed, on the basis of the S. pseudintermedius ED99 
complete genome deposited in Genbank, a new pair of primers for hlb 
gene, which enable the analysis of S. pseudintermedius strains. Their 
data together with species-specific nuc gene and multilocus sequence 
typing allow to better identify S. pseudintermedius and overcome the 
many difficulties in the differentiation among the species of the SIG 
group.  
Furthermore, Bannoehr et al. (2009) developed a rapid, simple and 
inexpensive PCR-restriction fragment length polymorphism (RFLP) 
which allows the discrimination of S. pseudintermedius from the 
closely related SIG members through the sequence analysis of the pta 
gene (Bannoehr et al., 2009).  
 
Multilocus sequence typing (MLST) is a nucleotide sequence-based 
method, which defines strains from the sequences of internal fragments 
of 7 housekeeping genes, in order to define a sequence type (ST) 
(Aanensen and Spratt, 2005). New sequence types are assigned when a 
new allelic profile is obtained. Even though MLST is a very expensive 
technique, it is the best method for genetic screening (Deurenberg and 
Stobberingh, 2008) and for a reliable discrimination of clinical isolates 
of S. pseudintermedius, which has a considerable genetic diversity 
within the species (Fitzgerald, 2009). So, from this point of view, 
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MLST appears to be the most effective method used to classify bacteria 
into clonal lineages and provide information about their relatedness. 
On the other hand, the molecular tools can be performed only in few 
diagnostic and clinical laboratories and require at least 24-36 hours for 
the results, so in the last years the use of matrix assisted laser 
desorption ionization time of flight mass spectrometry (MALDI-TOF 
MS) has notably increased (Fig 1.7). MALDI-TOF MS allows a rapid 
bacterial characterization and identification with high accuracy by a 
proteomic approach. Precisely, identification by MALDI-TOF MS is 
based on the analysis of protein spectrum from bacterial ribosome. 
Hence, this technique produces a fingerprint spectrum of the peptides 
and proteins of the analyzed bacterial strains. The extraction protocols 
are several, either prescribed by MALDI-TOF MS manufacturers or 
published in literature, and they are specific for certain groups of 
bacteria and yeasts. Referring to S. pseudintermedius or, better, to the 
SIG complex, Decristophoris et al. (2011), reported that, MALDI-TOF 
MS, provided with a reliable database, is a valid and effective 
technique for a rapid identification of the bacterial species belonging to 
the S. intermedius Group. 
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Fig. 1.7 Typical workflow of new and old methods used in clinical microbiology 
(Lavigne et al., 2012)  
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2. Materials and Methods 
 
2.1 Collection of samples 
During the years 2015-2017 the specimens, represented by auricular 
and cutaneous swabs, were collected from dogs suffering from otitis 
externa and pyoderma at the Bacteriology laboratory of the Veterinary 
Teaching Hospital of the Department of Veterinary Medicine and 
Animal Production, University of Naples “Federico II”.  
Moreover, further auricular swabs, screened for staphylococci growth, 
were obtained from Provet Lab srl of Latina, Lazio Region.  
From a total of 259 staphylococcal cultures, S. pseudintermedius strains 
were selected. 
 
2.2 Bacterial isolation and phenotypic identification of the isolates 
All samples were cultured and streaked in parallel on Columbia CNA 
agar (Liofilchem, Teramo, Italy) and on MSA (Liofilchem, Teramo, 
Italy) and incubated aerobically at 37 °C for 24-48 h (Fig. 1.8). As 
positive control S. pseudintermedius ATCC® (American Type Culture 
Collection) 49444TM was used. Suspected S. pseudintermedius isolates 
were firstly identified by using standard, rapid screening techniques: 
colony morphology, β-haemolysis on Columbia CNA agar, absence of 
mannitol fermentation on MSA, cellular morphology (after Gram’s 
staining method), catalase test. Additionally, each mannitol salt 
negative colony was also subjected to staphylocoagulase (tube 
coagulase) reaction (Oxoid, Ltd, UK) to confirm their capacity to 
produce coagulase enzyme.  
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Fig. 1.8 Culture media used for S. pseudintermedius isolation 
Columbia CNA agar on the left, MSA on the right 
                                             
                                        
For an initial identification, a biochemically-based commercial system, 
manual API Staph (bioMérieux, Marcy L’Etoile, France) was 
performed and the presumptive S. pseudintermedius strains, reported as 
S. intermedius, if of animal origin, were selected. These strains were 
then identified by MALDI-TOF MS analysis (Bruker Daltonics, 
Germany), which discriminates S. pseudintermedius from S. 
intermedius, at the diagnostic service of the Department of 
Experimental Medicine, University of Campania “Luigi Vanvitelli”. 
For MALDI-TOF MS identification, fresh colonies, grown on 
Columbia CNA agar, were used. 
The protocol used was the following: the bacterial colony was first 
inoculated in the plate for mass spectrometry. Subsequently, 1 µl of the 
organic matrix, usually cinnamic acid, was added to the sample. 
Afterwards, the plate was placed in the equipment for MALDI-TOF 
MS analysis (Fig. 1.9). The identification by MALDI-TOF MS is based 
on the score value released by equipment’s instructions.  
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Values from 2.3 to 1.9 indicated the best identification of genus and 
species (Santos et al., 2013). 
 
 
 
 
    
          Fig. 1.9 Maldi-Tof MS technique (Navrátilová et al., 2016) 
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All S. pseudintermedius cultures were stored at -70 °C by using 
Microbank™ vials (Pro-lab Diagnostics, Canada) for further analysis. 
Microbank™ is a ready to use system designed for the long term 
storage and retrieval of bacterial and fungal isolates. Each Microbank™ 
vial contains a 25 sterile coloured beads (single colour) and the 
cryopreservative. The specially treated beads are of a porous nature 
allowing microorganisms to readily adhere onto the bead surface (Fig. 
1.10). After inoculation the Microbank™ vials are kept at -70°C for 
extended storage. When a fresh culture is required, a single bead is 
easily removed from the Microbank™ vial and used to directly 
inoculate a suitable culture medium. 
 
 
Fig. 1.10 Microbank™: preservation and retrieval procedure (Pro-lab Diagnostics) 
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2.3 Genotypic identification of the isolates 
For the molecular characterization of the selected strains, each S. 
pseudintermedius isolate was cultured again on MSA with incubation at 
37°C overnight. The bacterial DNA extraction of the isolates was 
carried out using two different protocols:  
- by boiling;  
- by using a commercial kit. 
Referring to the first method, 1-5 colonies were taken from a pure 
culture of the isolated strain and then homogenized in 50 µL of distilled 
water and then denatured at 100°C for 10 minutes. Then, the obtained 
bacterial suspensions were stored at -20°C.   
The second technique was performed by using the commercial Isolate 
II Genomic DNA Kit (Bioline, London, UK) and following the 
manufacturer’s instructions. Briefly, the isolated bacterial colonies 
were dissolved in 180 µL of lysis buffer (buffer GL) and in 25 µL of 
proteinase K solution and then the obtained suspension was vortexed. 
At that point, the suspension was incubated at 56°C for at least one 
hour, in order to obtain the complete bacterial cell lysis. Subsequently, 
200 µL of buffer G3 were added, followed by another incubation at 
70°C for 10-15 minutes. The sample was, then, briefly vortexed and 
210 µL of absolute ethanol were added to it and the suspension was 
vigorously vortexed. The mix of each sample, placed in the isolate II 
genomic DNA spin column, was transferred into a collection tube and 
centrifuged at 11.000 x g for 1 minute. Afterwards, the silica membrane 
was washed twice with two different wash buffers (500 µL of wash 
buffer G1 and 600 µL of wash buffer G2) and, obviously, centrifugated 
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at each wash at 11.000 x g for 1 minute. This last step ensured that no 
ethanol residue was transported in the subsequent elution step. Once 
placed the isolate II genomic DNA spin column in a 1.5 ml sterile 
microcentrifuge tube, 100 µL of elution buffer G (elution step) were 
directly pipetted onto the silica membrane. The last centrifugation at 
11.000 x g for 1 minute allowed the collection of bacterial DNA in 
elution liquid in the Eppendorf tubes. Before the molecular 
characterization of all isolated strains, genomic DNA was tested by 
Biophotometer Eppendorf to determine the absorbance ratio (OD 
A260/A280). The A260/A280 was considered appreciable when ranged 
between 1.5-1.9 value. Bacterial DNA was stored at -20°C and used for 
further studies.   
 
Molecular profiling, using species-specific nuc gene (Sasaki et al., 
2010) and species-specific hlb gene (Kmieciak et al., 2016) was 
performed by single PCR to confirm the identification of S. 
pseudintermedius strains. Also for the genotypic characterization of the 
isolated strains, S. pseudintermedius ATCC® 49444TM was used as 
positive control.  
 Primers sequences, amplicon sizes and amplification programs are 
reported in Table 1.1. 
The single PCR reaction mixture for each gene (nuc and hlb genes) was 
prepared by using the Green Hot Start PCR Master Mix Direct Load, 
2x (Biotechrabbit, GmbH, Germany) as follows: 
- Green Hot Start PCR Master Mix: 12,5 µL 
- primers (F+R): 1 µL 
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- nuclease free water: 10,5 µL 
- DNA template: 1 µL 
The mixture final volume for one reaction was of 25 µL.  
For every PCR reaction there was always a positive and a negative 
control.  Genomic DNA was amplified using Biorad T100TM Thermo 
cycler (BioRad, Hercules, CA). 
 
Tab. 1.1. Primers sequences, amplicon sizes, amplification programs 
 
The amplified products were analyzed by gel electrophoresis. 1.5 g of 
agarose (Agarose electrophoresis grade, Gibco BRL) were placed in a 
flask and dissolved by heating in a microwave oven in 100 ml of TBE 
1X for few minutes. Once melted the agarose, in order to stain the gel, 
2 μL of Real Safe nucleic acid staining solution (Durviz s.l., Valencia, 
Spain) were added. At this point, the gel was poured into the 
appropriate bed equipped with a comb for the formation of wells and 
left to solidify for about 30 minutes.  For each sample, 12 µL of PCR 
Gene 
Primer sequences 
(5’-3’ sense and antisense) 
Amplicon 
size (bp) 
Amplification program 
nuc 
F: TRGGCAGTAGGATTCGTTAA 
R: CTTTTGTGCTYCMTTTTGG 
926 
94°C 5 min; 
94°C 30 s, 58°C 60s, 72°C 90s, 
for 30 cycles; 
72°C 5 min. 
 
hlb 
F: GACGAAAATCAAGCGGAA 
R: TCTAAATACTCTGGCGCAC 
734 
94°C 2:30 min; 
94°C 30s, 56°c 30s, 72°C 1min, 
for 30 cycles; 
72°C 10 min. 
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reaction mix were loaded in each gel well. 5 μL of 100 bp DNA ladder 
with 6x loading dye, consisting of 100- 3000 bp, were loaded as 
molecular marker (Biotechrabbit, GmbH, Germany).  
Electrophoresis was performed in a BioRad electrophoresis tank with 
1X TBE as running buffer at 80V for 45-50 minutes. Electrophoresed 
gels were visualized under blue-light and their images taken using the 
ChemiDocTM XRS+ with Image LabTM Software (BioRad, Hercules, 
CA). 
 
3. Results 
 
3.1 S. pseudintemedius isolation and phenotypic identification  
During the years 2015-2017, a total of 259 staphylococcal strains 
responsible for canine skin disorders were collected. The phenotypic 
bacterial identification by proteomic profiling defined a relevant 
number of 126 (49%) S. pseudintermedius strains. Moreover, all the 
isolated S. pseudintermedius strains were identified with good scores 
(1.9 or 2.0).   
The other most isolated species belonged to S. aureus (8%), S. 
schleiferi (7%), S. xylosus (6%), S. sciuri (2%), S. intermedius (2%), S. 
delphini (1%).                                                                                                                              
The remaining 25% consisted of unsuspected Staphylococcus spp. 
S. pseudintermedius strains were recovered from dogs suffering with 
otitis externa (84%) and pyoderma (16%), originating from two 
different Italian geographical areas (Naples, Campania Region [52%] 
and Latina, Lazio Region [48%]). The Table 1.2 describes the 
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percentage of S. pseudintermedius isolates from the above reported 
canine skin disorders. 
 
Tab. 1.2 S. pseudintermedius strains isolated from diseased dogs of 
Campania and Lazio regions 
 
Geographical area 
of origin 
Biological origin  % isolated 
S.pseudintermedius 
strains 
 
Naples otitis 
pyoderma 
71 
29 
   
Latina otitis 
pyoderma 
98 
2 
 
All the isolated S. pseudintermedius strains appeared to be β-
heamolytic on Colombia CNA agar and mannitol negative on MSA 
(Fig 1.11). Furthermore, they were positive at the staphylocoagulase 
and catalase reactions. 
                                        
                                 
 
Fig. 1.11 S. pseudintermedius growth on MSA 
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3.2 S. pseudintermedius genotypic identification   
All 126 S. pseudintermedius strains harboured the species-specific nuc 
and hlb genes (Fig. 1.12, 1.13) confirming, thus, the proteomic 
identification by MALDI TOF MS.   
 
 
 
 
Fig. 1.12 Molecular characterization of S. pseudintermedius: PCR for detection of 
species-specific nuc gene. Data from one of three experiments are shown. 
Lanes 3,4,6,7,8, positive samples; Lane P+, positive control; lane N-, negative 
control; lane M, 100-bp DNA ladder. 
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Fig. 1.13 Molecular characterization of S. pseudintermedius: PCR for detection of 
species-specific hlb gene. Data from one of three experiments are shown. 
    Lanes 33,36,39,51,54,67,70,75,77,83,84,92, positive samples; lane N-, negative 
control; lane M, 100-bp DNA ladder. 
                        
 
 
 
4. Discussion and conclusions 
 
Bacterial otitis externa and pyoderma are the most common canine skin 
diseases and Staphylococcus pseudintermedius is the staphylococcal 
species most frequently isolated from dogs suffering from these 
infections. In fact, Staphylococcus pseudintemedius, an opportunistic 
canine skin pathogen, is the major CoPS that inhabits healthy dogs 
(Gόmez-Sanz et al., 2013). In particular conditions, such as dog injures 
or sickness, this species can take advantage of the weakened defenses 
and cause infection and illness.  
According to literature, the results of this study show a high prevalence 
(49%) of S. pseudintermedius among the other isolated staphylococcal 
species, approving its role as the main causative agent of canine skin 
disorders. 
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Due to the high rates of colonization of dogs with S. pseudintermedius 
and S. aureus, these species make up the majority of Staphylococcus 
related infections in dogs. According to this finding also the results of 
this research reported S. aureus as the second most common causative 
agent of staphylococcal skin infection. 
The literature has always reported a higher interest for coagulase-
positive staphylococci such as S. aureus and SIG, which is composed, 
besides S. pseudintermdius, by S. intermedius and S. delphini which, 
here, were found responsible agents of canine skin disorders with 
percentage in the range of 1-8%. 
 
Even though S. intermedius mainly colonizes pigeons (Sasaki et al., 
2007), it was also isolated from dogs with otitis externa (Dziva et al., 
2015). 
Sasaki et al. (2007) found that S. intermedius can be chemically 
distinguished from S. pseudintermedius by positive arginine 
dihydrolase and acid production from beta-gentiobiose and D-mannitol. 
The two species can also be distinguished using molecular and genetic 
testing, as well as MALDI-TOF mass spectrometry, although this is not 
commonly done (Wang et al., 2013). 
Furthermore, S. intermedius should be included in the differential 
diagnosis of invasive infection amongst human patients with close 
contact with dogs.  
 
S. delphini, first isolated from a dolphin (Varaldo et al. 1988), was also 
found in several different species including horse, mink, pigeons and 
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camels. These data indicate that S. delphini may be more widespread 
and clinically important than was previously thought. Surprisingly, in 
this study, this staphylococcal species was isolated from infected dogs 
(3/259, 1%), therefore it should be warranted to examine the 
importance of S. delphini as a veterinary pathogen in pets.  
 
Coagulase-Negative Staphylococci (CoNS), members of normal flora 
of human and animal skin, have long been considered as nonpathogenic 
possessing fewer virulence properties than CoPS. Recently they have 
assumed an important role as pathogens in skin and soft tissue 
infections, overall, because of their increasing multidrug-resistance 
profiles. 
In this regard, the percentage of CoNS positivity (15%), precisely of S. 
schleiferi, S. xylosus and S. sciuri, among the processed samples, 
highlights a relevant dog susceptibility to these bacterial species. 
In veterinary medicine, S. schleiferi has been repeatedly documented in 
literature as both an inhabitant and as a pathogen, and May et al. (2012) 
demonstrated that S. schleiferi could be recovered from the ears and 
anterior nares of healthy dogs as well as those with otitis and/or 
pyoderma. In this study, S. schleiferi was isolated from 20/259 samples 
(7%) followed by S. xylosus (6%) and S. sciuri (2%). 
 
In conclusion, this study underlines that S. pseudintermedius is the 
most common bacterial isolate from dogs suffering with otitis externa 
and pyoderma in Naples – Campania Region, and Latina, Lazio 
Region. 
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However, its phenotypic identification remains problematic in many 
clinical microbiology laboratories, especially in the human ones, where 
it is often misidentified as S. aureus or CoNS. So, genotypic profiling 
(species-specific nuc and hlb genes) still represents the main molecular 
technique for the identification of this species when MALDI-TOF MS 
analysis is not available.  
MALDI-TOF MS for the diagnosis of infectious diseases has been 
rapidly embraced by laboratories around the globe, and, as seen in this 
study, represents a valid bacterial identification method also in 
veterinary medicine. In fact, it represents the most accurate and rapid 
method for the identification of S. pseudintermedius and the other 
members of the SIG.  
 
This study has provided a further evidence that MALDI-TOF MS is a 
useful and reliable technique for S. pseudintermedius identification. 
Further confirmation of proteomic profiling identification by MALDI-
TOF MS was always given by genotypic profiling results, linked to the 
detection of species-specific S. pseudintermdius genes.  
 
References  
66 
 
5. References 
Aanensen DM, Spratt BG, 2005. The multilocus sequence typing    
network: mlst.net. Nucleic Acids Res 33, W728–W733. 
Bannoehr J, Ben Zakour NL, Waller AS, Guardabassi L, Thoday KL,  
van den Broek AH, Fitzgerald JR, 2007.  Population genetic 
structure of the Staphylococcus intermedius group: insights into agr 
diversification and the emergence of methicillin-resistant strains. J 
Bacteriol 189, 8685-8692. 
Bannoehr J, Franco A, Iurescia M, Battisti A, Fitzgerald JR, 2009.  
Molecular diagnostic identification of Staphylococcus 
pseudintermedius. J Clin Microbiol 47, 469-471. 
Bannoehr J, Guardabassi L, 2012. Staphylococcus pseudintermedius in  
the dog: taxonomy, diagnostics, ecology, epidemiology and 
pathogenicity. Vet Dermatol 23, 253-266.  
Ben Zakour NL, Bannoehr J, van den Broek AH, Fitzgerald JR, 2011.  
Complete genome sequence of the canine pathogen Staphylococcus 
pseudintermedius. J Bacteriol 193, 2363-2364. 
Casagrande Proietti P, Stefanetti V, Hyatt DR, Marenzoni ML,  
Capomaccio S, Coletti M, Bietta A, Franciosini MP, Passamonti F, 
2015. Phenotypic and genotypic characterization of canine 
pyoderma isolates of Staphylococcus pseudintermedius for biofilm 
formation. J Vet Med Sci 77, 945-951. 
Decristophoris P, Fasola A, Benagli C, Tonolla M, Petrini O, 2011.  
Identification of Staphylococcus intermedius Group by MALDI-
TOF MS. Syst Appl Microbiol 34, 45-51. 
References  
67 
 
De Martino L, Nocera FP, Mallardo K, Nizza S, Masturzo E, Fiorito F, 
Iovane G, Catalanotti P, 2016. An update on microbiological causes of  
canine otitis externa in Campania Region, Italy. Asian Pac J Trop 
Biomed 6, 384-389. 
Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman AC,  
Stobberingh EE, 2007. The molecular evolution of methicillin-
resistant of Staphylococcus aureus. Clin Microbiol Infect 13, 222-
235. 
Deurenberg RH, Stobberingh EE, 2008. The evolution of 
Staphylococcus aureus. Infect Genet Evol 8, 747-763. 
Devriese LA, Vancanneyt M, Baele M, Vaneechoutte M, De Graef E,  
Snauwaert C, Cleenwerck I, Dawyndt P, Swings J, Decostere A, 
Haesebrouck F, 2005. Staphylococcus pseudintermedius sp. nov., a 
coagulase-positive species from animals. Int J Syst Evol Microbiol 
55, 1569-1573.  
Dufour P, Jarraud S, Vandenesch F, Greenland T, Novick RP, Bes M,  
Etienne J, Lina G, 2002. High genetic variability of the agr locus in 
Staphylococcus species. J Bacteriol 184, 1180-1186. 
Duim B, Verstappen KMHW, Kalupahana RS, Ranathunga L, Fluit  
AC, Wagenaar JA, 2018. Methicillin-resistant Staphylococcus 
pseudintermedius among dogs in the description of novel SCCmec 
variants. Vet Microbiol 213, 136-141. 
Dziva F, Wint C, Auguste T, Heeraman C, Dacon C, Yu P, Koma LM,  
2015. First identificationof methicillin-resistant Staphylococcus 
pseudintermedius strains among coagulase-positive staphylococci 
References  
68 
 
isolated from dogs with otitis externa in Trinidad, West Indies. 
Infect Ecol Epidemiol 5, 29170. 
Fitzgerald JR, 2009. The Staphylococcus intermedius group of bacterial  
pathogens: species reclassification, pathogenesis and the emergence 
of methicillin resistance. Vet Dermatol 20, 490-495. 
Foglia Manzillo V, Nocera FP, De Martino L, Gizzarelli M, Oliva G,  
2016.  A successful vancomycin treatment of multidrug-resistant 
MRSA-associated canine pyoderma. J Dermatol Res Ther 1, 12-18. 
Garbacz K, Zarnowska S, Piechowcz L, Haras K, 2013. Pathogenicity  
potential of Staphylococcus pseudintermedius strains isolated from 
canine carriers and from dogs with infection signs. Virulence 4, 255-
259.  
Gόmez-Sanz E, Torres C, Lozano C, Zarazaga M, 2013. High diversity  
of Staphylococcus aureus and Staphylococcus pseudintermedius 
lineages and toxigenic traits in healthy pet-owing household 
members. Underestimating normal household contact? Comp 
Immunol Microbiol Infec Dis 36, 83-94. 
Han JI, Yang CH, Park HM, 2015. Emergence of biofilm-producing  
Staphylococcus pseudintermedius isolated from healthy dogs in 
South Korea. Vet Q 36, 207-210. 
Hájek V, 1976. Staphylococcus intermedius, a new species isolated  
from animals. Int J Syst Bacteriol 26, 401-406. 
Hariharan H, Coles M, Poole D, Lund L, Page R, 2006. Update on  
antimicrobial susceptibilities of bacterial isolates from canine and 
feline otitis externa. Can Vet J 47, 253-255. 
Iyori K, Hisatsune J, Kawakami T, Shibata S, Murayama N, Ide K,  
References  
69 
 
Nagata M, Fukata T, Iwasaki T, Oshima K, Hattori M, Sugai M, 
Nishifuji K, 2010. Identification of a novel Staphylococcus 
pseudintermedius exfoliative toxin gene and its prevalence in 
isolates from canines with pyoderma and healthy dogs. FEMS 
Microbiol Lett 312, 169-175. 
Kmieciak W, Szewczyk EM, Ciszewski M, 2016. Searching for beta- 
 haemolysin hlb gene in Staphylococcus pseudintermedius with 
species-specific primers. Curr Microbiol 73,148-152. 
Lavigne JP, Espinal P, Dunyach-Remy C, Messad N, Pantel A, Sotto  
A, 2013. Mass spectrometry: a revolution in clinical microbiology? 
Clin Chem Lab Med 51, 257-270. 
Loeffer A, Lyod DH, 2018. What has changed in canine pyoderma? A  
narrative review. Vet J 235, 73-82. 
Logas DB, 1994. Diseases of the ear canal. Vet Clin North Am Small  
Anim Pract 24, 905-919. 
Lozano C, Rezusta A, Ferrer I, Pérez-Laguna V, Zarazaga M, Ruiz-  
Ripa L, Revillo MJ, Torres C, 2017. Staphylococcus 
pseudintermedius human infection cases in Spain: dog-to-human 
transmission. Vector Borne Zoonotic Dis 17, 268-270. 
Liskova P, Vydrzalova M, Mazurova J, 2007. Identification and  
antimicrobial susceptibility of bacteria and yeasts isolated from 
healthy dogs and dogs with otitis externa. J Vet Med 54, 559-563. 
McAdow M, Missiakas DM, Schneewind O, 2012. Staphylococcus  
aureus secretes coagulase and von Willebrand factor binding protein 
to modify the coagulation cascade and establish host infections. J 
Innate Immun 4, 141–148. 
References  
70 
 
May ER, Kinyon JM, Noxon JO, 2012. Nasal carriage of  
Staphylococcus schleiferi from healthy dogs and dogs with otitis, 
pyoderma or both. Vet Microbiol 160, 443-448. 
Miller WH, Griffin CG, Campbell KL, 2013. Muller and Kirk’s small  
animal dermatology. 7th edn. Elsevier, St Louis,195. 
Moodley A, Stegger M, Ben Zakour NL, Fitzgerald JR, 2009. Tandem  
repeat sequence analysis of staphylococcal protein A (spa) gene in 
methicillin-resistant Staphylococcus pseudintermedius. Vet 
Microbiol 135, 320–326. 
Moodley A, Riley MC, Kania SA, Guardabassi L, 2013. Genome  
sequence of Staphylococcus pseudintermedius strain E140, an ST71 
European associated methicillin-resistant isolate. GenomeA 1, 
e00207-12. 
Navrátilová L, Procházková P, Bardoň J, Novotný R, Zápalka M,  
Jakubec P, Zatloukal J, Kolek V, Kopřiva F, Flodrová P, Raclavský 
V, 2016. Performance of pyrosequencing versus MALDI-TOF MS 
in bacteria identification in chronic lung disease. J Biol Methods 3, 
e52. 
Robb AR, Wright ED, Foster AME, Walker R, Malone C, 2017.  
Skin infection caused by a novel strain of Staphylococcus 
pseudintermedius in a Siberian husky dog owner. JJM Case Rep 4, 
jmmcr005087. 
Rosser EJ, 2004. Causes of otitis externa. Vet Clin North Am Small  
Anim Pract 34, 459-468. 
Santos AF, Cayô R, Schandert L, Gales AC, 2013. Evaluation of  
References  
71 
 
MALDI-TOF MS in the microbiology laboratory. J Bras Patol Med 
Lab 49, 191-197. 
Sasaki T, Kikuchi K, Tanaka Y, Takahashi N, Kamata S, Hiramatsu K,  
2007. Reclassification of phenotypically identified Staphylococcus 
intermedius strains. J Clin Microbiol 45, 2770-2778 
Sasaki T, Tsubakishita S, Tanaka Y, Sakusabe A, Ohtsuka M, Hirotaki  
S, Kawakami T, Fukata T, Hiramatsu K, 2010. Multiplex-PCR 
method for species identification of coagulase-positive 
staphylococci. J Clin Microbiol 48, 765-769. 
Somayaji R, Rubin JE, Priyantha MA, Church D, 2016. Exploring  
Staphylococcus pseudintermedius: an emerging zoonotic pathogen? 
Future Microbiol 11, 1371-1374.  
Stegmann R, Burnens A, Maranta CA, Perreten V, 2010. Human  
infection associated with methicillin-resistant Staphylococcus 
pseudintermedius ST71. J Antimicrob Chemoter 65, 2047-2048. 
Tse H, Tsoi HW, Leung SP, Urguhart IJ, Lau SK, Woo PC, Yuen KY.  
Complete genome sequence of the veterinary pathogen 
Staphylococcus pseudintermedius strain HKU10-03, isolate in a case 
of canine pyoderma. J Bacteriol 193, 1783-1784.  
van Duijkeren E, Kamphuis MIC, Mije V, Laarhoven LM, Duim B,  
Wagenaar JA, Houwers DJ, 2011. Staphylococcus pseudintermedius 
between infected dogs and cats and contact pets, humans and the 
environment in households and veterinary clinics. Vet Microbiol 
150, 338-343. 
Van Hoovels L, Vankeerberghen A, Boel A, Van Vaerenbergh K, De  
References  
72 
 
Beenhouwer H, 2006. First case of Staphylococcus 
pseudintermedius infection in a human. J Clin Microbiol 44, 4609-
4612. 
Varaldo PE, Kilpper-Balz R, Biavasco F, Satta G, Schleifer KH, 1988.  
Staphylococcus delphini sp. nov. a coagulase-positive species 
isolated from dolphins. Int J Syst Bacteriol 38, 436-439. 
Wang N, Neilan AM, Klompas M, 2013. Staphylococcus intermedius  
infections: case report and literature review. Infect Dis Rep 22, e3.  
Weese JS, van Duijkeren E, 2010. Methicillin-resistant Staphylococcus  
aureus and Staphylococcus pseudintermedius in veterinary 
medicine. Vet Microbiol 140, 418-429. 
Władyka B, Pustelny K 2008. Regulation of bacterial protease activity.  
Cell Mol Biol Lett 13, 212-229. 
Zur G, Lifshitz B, Bdolah-Abram T, 2011. The association between  
signalment, common causesof canine otitis externa and pathogens.  
J Small Anim Pract 52, 254-258. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                    
Chapter 2  
Antibiotic resistance in Staphylococcus pseudintermedius 
 The spread of methicillin-resistant and methicillin-susceptible  
S. pseudintermedius strains 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibiotic resistance in clinical S. pseudintermedius strains  
75 
 
1. Introduction  
The rate and the spread of antimicrobial resistance in bacteria has 
increased in recent years. The World Health Organization (WHO) 
defines antimicrobial resistance as the “…resistance of a 
microorganism to an antimicrobial drug that was originally effective for 
treatment of infections caused by it” (WHO, 2014). Precisely, it is 
worth noting that the use of antimicrobial drugs has a tendency to select 
for resistant bacteria already present in the population, rather than 
inducing resistance (Hirsh et al., 2004; Quinn et al., 2011).  
Resistance to antimicrobial drugs can be due to acquired resistance, 
either by mutation in the chromosomal DNA, or by acquiring genetic 
material. Chromosomal mutation often leads to a change in the 
bacterial structure, for example altered antimicrobial target proteins. 
These rare, spontaneous changes in the bacterial DNA are linked to 
mistakes during DNA replication and are not caused by the presence of 
antibiotics. Mutations in genes leading to expression of efflux proteins 
can induce multiple antibiotic resistances (Fig. 2.1) (Hirsh et al., 2004; 
Quinn et al., 2011). 
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Fig. 2.1 Bacterial antimicrobial resistance mechanisms 
 
The mechanism that has an important role in the development of 
antibiotic resistance is the exchange of transferable DNA structures, 
usually plasmids, operons and transposons. These mobile gene 
elements carrying resistance genes can be spread to other bacteria by 
different mechanisms (Fig. 2.2): 
• Transduction – DNA incorporated in bacterial phages (virus that 
infects bacteria) and transferred between bacteria by phages. 
• Conjugation – The transfer of plasmid or chromosomal DNA from 
donor to recipient through a sex pilus. 
• Transformation – The ability of certain bacteria genera to pick up 
naked DNA from the environment. 
• Transposition – Gene segments can change position within the 
bacterial genome. 
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• Integrons – Consists of an intergrase gene that can capture gene 
cassettes coding for antibiotic resistance. 
 
 
 
 
Fig. 2.2 Mobile gene elements (Fang, 2015) 
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1.1 Antimicrobial resistance in Staphylococcus pseudintermedius 
Referring to S. pseudintermedius, in the past the isolates were generally 
susceptible to β-lactam antibiotics (MSSP), but, since 2006, MRSP has 
emerged as a significant health problem in pet animals. The first 
phenotypic MRSP strains were isolated in France in the mid-1980 from 
healthy dogs and dogs affected by pyoderma (Pellerin et al., 1998).  In 
1999, the first mecA positive strain was described as responsible of 
canine pyoderma in US (Gortel et al., 1999) and in Europe in 2005 
(Loeffler et al., 2007). Compared with MRSA, the emergence of MRSP 
is of greater concern for veterinary patients as S. pseudintermedius is 
the primary staphylococcal species inhabiting healthy dogs and cats, 
where it can cause a great variety of infections. Moreover, MRSP has 
been reported with an increasing frequency (Loeffler et al., 2007; van 
Duijkeren et al., 2011; Kasai et al., 2016) and MRSP strains show often 
multidrug resistance profiles worldwide, including resistance to several 
classes of antimicrobial drugs (Perreten et al., 2010). This limits the 
treatment options and represents a relevant threat to small animal 
therapy in veterinary medicine, challenging infection control measures 
(van Duijkeren et al., 2011, Bannoehr and Guardabassi, 2012; Bond 
and Loeffler, 2012). In fact, there are several reports on isolates 
resistant almost to all antimicrobials authorized for use in veterinary 
medicine (Wettstein et al., 2008; Perreten et al., 2010) inducing 
veterinarians to use antimicrobials authorized for human medicine 
(Weese and van Duijkeren, 2010).  
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1.1.1 Methicillin resistance in S. pseudintermedius 
In Staphylococcus pseudintermedius, as in MRSA, methicillin 
resistance is mediated by the mecA gene, which is conferred by the 
acquisition of one of the several staphylococcal cassette chromosome 
mec (SCCmec) elements (Weese and van Duijkeren, 2010; Cartwright 
et al., 2013). The SCCmec element can be transferred between different 
staphylococcal species (Wielders et al., 2001). Differently from MRSA, 
in MRSP only 5 SCCmec elements have been completely 
characterized. The different types of SCCmec elements found in MRSP 
are SCCmec II-III, SCCmec III, SCCmec IV, SCCmec V, SCCmec VII 
and other nontypeable cassettes (Perreten et al., 2013; McCarthy et al., 
2015). 
MecA gene encodes a modified penicillin-binding protein (PBP2a) with 
low affinity for β-lactams, including cephalosporins. Normally, β-
lactam antibiotics interact with the PBP of S. pseudintermedius to 
prevent cell wall construction. However, in MRSP, the antibiotics 
cannot inhibit the enzyme and fail to exercise its inhibitory effect on 
bacterial growth (van Duijkeren et al., 2011). Although methicillin is 
no longer used in clinical practice, the term “methicillin-resistant” has 
persisted and has been used to indicate strains that are resistant to all 
beta-lactams (Morris et al., 2017). So, it still represents a marker for 
broad resistance to all β- lactams and an indicator of likely nosocomial 
epidemiology and additional multidrug resistance. Precisely, in most 
veterinary diagnostic laboratories the methicillin resistance is generally 
evaluated by phenotypic methods. Commonly, oxacillin or cefoxitin is 
used in place of the no more produced methicillin. However, in S. 
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pseudintermedius cefoxitin disc diffusion testing as screening test for 
methicillin resistance has been reported as a poorer predictor (Bemis et 
al., 2009). So, it appears to be inappropriate for its many false negative 
results and it is not recommended currently by the Clinical Laboratory 
Standards Institute (CLSI). Thus, oxacillin disc diffusion testing is the 
one to prefer and use. In particular, as suggested by CLSI, an oxacillin 
MIC breakpoint R ≥ 0.5 mg/L and disc diffusion breakpoint R ≤ 17 mm 
are highly correlated with the detection of mecA in S. pseudintermedius 
(van Duijkeren et al., 2011). In any case, the gold standard, or better, 
the most reliable test for the detection of mecA gene is PCR (Paterson 
et al., 2014). In recent years, another gene responsible for methicillin 
resistance has been described in S. aureus: mecA homologue termed 
mecC (formerly mecALGA251). Since its original description, it has been 
reported in S. aureus isolates of many countries (Paterson et al., 2012; 
Cartwright et al., 2013), but until now never described in S. 
pseudintermedius isolates.  
As MRSA is considered to be a major nosocomial pathogen amongst 
humans worldwide (Graffunder and Venezia, 2002), MRSP embodies 
the corresponding threat amongst dogs in veterinary medicine. Indeed, 
many studies underline that hospitalization, frequent visits to veterinary 
practices, and prior antimicrobial administration are recognized risk 
factors for canine MRSP infection and carriage (Nienhoff et al., 2011; 
Weese et al., 2012; Eckholm et al., 2013; Lehner et al., 2014; Grönthal 
et al., 2017). One reason could be the direct transmission between dogs 
in the veterinary clinics, since dogs can carry MRSP for at least six 
months after acquisition (Bergström et al., 2012). Another reason is the 
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possible risk of indirect transmission between dogs via environmental 
surfaces in hospitals.  
 
1.1.2 Resistance to non-β-lactam antibiotics in S. 
pseudintermedius 
It is well known that MRSP isolates are resistant to several of non-β-
lactam antibiotics, showing multidrug resistance profiles. 
Characteristically, MRSP are more often multidrug-resistant strains 
(MDR) than MSSP. However, an increasing trend of resistance to the 
penicillinase-labile penicillins amongst MSSP has occurred in the last 
years (Moodley et al., 2014). The Clinical and Laboratory Standards 
Institute (CLSI) defined that multidrug resistance should exclusively be 
referred to acquired resistance properties. Particularly, MRSP, as 
MRSA, is defined as MDR when it is not susceptible to at least one 
agent in three or more antimicrobial categories (Magiorakos et al., 
2012). 
Multiresistance in S. pseudintermedius includes resistance to 
tetracyclines, macrolides, lincosamides, aminoglycosides, 
streptogramins, trimethoprim-sulfamethoxazole and fluoroquinolones, 
as reported worldwide (Perreten et al., 2010; Weese and van Duijkeren, 
2010; van Duijkeren et al., 2011; Cain, 2013). Currently, it is common 
to isolate MRSP strains that are susceptible to very few antimicrobials. 
Generally, they are susceptible only to amikacin, rifampicin, 
vancomycin and linezolid. This denotes a true therapeutic dilemma, 
due both to potential drug toxicities (amikacin and rifampicin) and 
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ethical use considerations (vancomycin and linezolid) (Morris et al. 
2017).  
Referring to tetracycline resistance, it is common in staphylococci and 
genotypically mediated by tet genes, whose acquisition is generally 
associated with transposons or plasmids. TetK, tetL, tetM and tetO are 
the four major genes associated with tetracycline resistance amongst 
Gram-positive bacteria. TetK and tetL genes encode for efflux proteins, 
which prevent the accumulation of tetracycline within the cell. TetM 
and tetO encode for ribosomial protection proteins, reducing the 
affinity of tetracycline to the ribosome. The distribution of tet genes is 
different among Gram-positive cocci: tetL and tetO are generally 
detected in streptococci and enterococci, while tetK is often found 
alone or in combination with tetM in staphylococci (Bismuth et al., 
1990). Precisely, tetK gene is located in small plasmids (from 4.3 to  
4.7 kbps). The prototype of these plasmids, called pT181, is commonly 
isolated in S. aureus. Plasmids closely related to pT181 have been 
identified in all staphylococcal species of animal origin (Schwarz et al., 
2000).  
The tetM gene is located on conjugative transposons of enterococcal 
origin, such as the Tn916 or Tn1545 (Roberts, 1996).  
The most commonly genes expressed by S. pseudintermedius are tetM 
and tetK. Generally, S. pseudintermedius strains which harbour only 
tetK maintain susceptibility to minocycline but not to other 
tetracyclines, while strains carrying tetM tend to exhibit cross 
resistance to minocycline and other tetracyclines (Youn et al., 2014; 
Morris et al., 2017). 
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Staphylococcal resistance against erythromycin (class of macrolides) is 
commonly based on three mechanisms: modification of the target site, 
active efflux, enzymatic inactivation (Sutcliffe et al., 1996; Schwarz et 
al., 2000). The target modification, encoded by the erm genes, is the 
main resistance mechanism and occurs with the demethylation of an 
adenyl residue at the level of the 23S portion of the rRNA (Zou et al., 
2011). According to literature in animal and human staphylococci, 
resistance to erythromycin is due to erm genes. In staphylococci of 
animal origin ermA, ermB and ermC have been identified as 
responsible for resistance to erythromycin (Zou et al., 2011) and 
generally present individually.  
ErmA and ermB genes are commonly found in small transposons such 
as the Tn544 and the Tn917 / Tn551 (Werckenthin and Schwarz, 2001). 
ErmC gene is generally found in small multi-copy plasmids and this 
gene is predominant in staphylococcal isolates from both humans and 
animals, particularly in S. hyicus and other porcine staphylococci (de 
Vries et al., 2012). 
In contrast, ermB gene is the most widespread in canine isolates of 
Staphylococcus pseudintermedius (Jensen et al., 1999; Boerlin et al., 
2001; Lüthje and Schwarz, 2007; Youn et al., 2014). 
Ben Zakour et al. (2012) identified four transposons harboring one or 
more antibiotic resistance genes in the genome of S. pseudintermedius 
ED99 (Table 2.1).  
In contrast to the other two species of the SIG, S. pseudintermedius 
comes across an extensive antibiotic selective pressure, which has 
allowed the spread of mobile genetic elements encoding antibiotic 
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resistance. Notably, S. pseudintermedius strains, harboring antibiotic 
resistance determinants on their mobile genetic elements, act as a 
reservoir of resistance genes that could easily spread to human skin 
flora (Guardabassi et al., 2004).  
 
Tab. 2.1 Mobile genetic elements associated with antibiotic resistance in S. 
pseudintermedius ED99 (Ben Zakour et al., 2012) 
 
Name Resistance factors Closest homologs 
 
Tn5801 
Tn552 
Tn554-like 
Tn5405 
tetM 
bla operon 
bla operon 
aad6-sat4-aphA-3, ermB 
S. aureus 
S. haemolyticus, S.epidermidis 
S. aureus 
Streptococcus sp., 
 Enterococcus faecium 
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2. Materials and Methods 
 
2.1 Antimicrobial susceptibility testing 
The antimicrobial susceptibility testing is a rapid and reliable 
technique, which is needed in order to reduce the risk of the spread of 
multidrug-resistant strains, often responsible for chronic infections. In 
fact, its results allow to choose the most appropriate therapeutic 
protocol for the treatment of the infection caused by a specific bacterial 
pathogen.   
The importance of the antibiogram is based on the principle that in 
vitro susceptibility prefigures the in vivo efficacy of an antibiotic 
therapy. Minimal inhibitory concentration (MIC) is objectively 
determined by antimicrobial susceptibility testing. MIC is defined as 
the lowest concentration of an antibacterial agent, that inhibits the 
growth of a bacterial isolate (Quinn et al., 2011). 
However, many phenotypic methods used in diagnostic laboratory, 
such as Kirby-Bauer disc diffusion method, give a semi-quantitative 
estimate of the MIC, which is obtained from two antibiotic 
concentration namely breakpoints. These breakpoints are established by 
the National Committee for Clinical Laboratory Standards (NCCLS), 
so that bacteria can be classified as susceptible (S), intermediate (I), or 
resistant (R) to specific antimicrobial agent.  
 
In this study, the antimicrobial susceptibility testing was performed on 
126 canine S. pseudintermedius isolates by using Kirby-Bauer disk 
diffusion method (Bauer et al., 1966) on Mueller-Hinton agar plates. 
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Kirby-Bauer disc diffusion method is the most used test, since it is a 
relatively simple and economical method, most suitable for testing 
rapidly aerobic bacteria. Herein, the bacterial suspension was prepared 
by selecting several morphologically similar colonies with a sterile 
cotton swab and homogenizing the colonies in a sterile saline solution 
(0.85% NaCl) (bioMérieux, Marcy L’Etoile, France) to the density of a 
McFarland 0.5 standard. Then, the bacterial sample was spread over the 
entire surface of Mueller-Hinton agar plate (Liofilchem, Teramo, Italy) 
and antimicrobial discs with specific amounts of antibiotics were 
placed on the inoculated surface plates. After incubation at 37°C for 24 
hours, the diameter of the inhibition zone of each tested antibiotic was 
measured in millimeters and interpreted as susceptible (S), intermediate 
(I) or resistant (R) compared to international standards. 
 
Based on Kirby-Bauer method, all the identified S. pseudintermedius 
strains, confirmed by the species-specific nuc and hlb PCR, 
respectively, were tested to the following 20 antibiotics: amoxicillin-
clavulanate (AMC, 20/10 μg), ampicillin (AMP, 10 μg), oxacillin (OX, 
1 μg), penicillin (P, 10 IU), cephalothin (KF, 30 μg), cefoxitin (FOX, 
30 μg), ceftriaxone (CRO, 30 μg), clindamycin (CD, 2 μg), 
ciprofloxacin (CIP, 30 μg), enrofloxacin (ENR, 5 μg), erythromycin (E, 
15 μg), gentamicin (CN, 10 μg), kanamycin (K, 30 μg), streptomycin 
(S, 10 μg), tobramycin (TOB, 10 μg), imipenem (IMI, 10 μg), linezolid 
(LNZ, 30 μg), sulfamethoxazole-trimethoprim (SXT, 1.25/23.75 μg), 
tetracycline (TE, 30 μg), vancomycin (VA, 30 μg). The isolates were 
classified as susceptible (S), intermediate (I) or resistant (R) according 
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to the Clinical and Laboratory Standards Institute guidelines (CLSI, 
2015). For streptomycin breakpoints employed were those 
recommended by the French Society for Microbiology 
(http://www.sfm-microbiologie.fr).  The antibiotic classes chosen and 
tested in this study are reported in Table 2.2. 
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 Tab. 2.2 Antibiotics and antibiotic classes tested for canine S. pseudintermedius isolates 
Antibiotics μg  Antibiotics by class 
  
 
Amoxicillin + 
clavulanate (AUG) 
 
30 
(20/10) 
 
Penicillin combination 
Ampicillin (AMP) 10 Penicillins 
Oxacillin (OX) 1 
Penicillin (P) 10 UI 
 
Cephalothin (KF) 30 Cephalosporins  
(first generation) 
Cefoxitin (FOX) 30 Cephalosporins 
 (second generation) 
Ceftriaxone (CRO) 30 Cephalosporins 
(third generation) 
Clindamycin (CD) 2 Lincosamides 
Ciprofloxacin (CIP) 30 Fluoroquinolones 
Enrofloxacin (ENR) 5 
Erythromycin (E) 15 Macrolides 
Gentamicin (CN) 10 Aminoglycosides 
Kanamycin (K) 30 
Streptomycin (S) 10 
Tobramycin (TOB) 10 
Imipenem (IMI) 10 Carbapenems 
Linezolid (LNZ) 30 Oxazolidinones 
Sulfamethoxazole-
Trimethoprim (SXT) 
25 
(1,25/23,75) 
Sulfonamides 
Tetracyclin (TE) 30 Tetracyclines 
Vancomycin (VA) 30 Glycopeptides 
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2.2 Genotypic characterization of antibiotic resistance 
After bacterial DNA extraction from S. pseudintermedius strains as 
already described in chapter 1, genetic profiles of antibiotic resistance 
by PCR for mecA and mecC genes and multiplex PCR for tetK, M, L, 
O and ermA, B, C genes were systematically performed on all 126 S. 
pseudintermedius isolates.  
 
2.2.1 Methicillin resistance determinants – molecular 
characterization of MRSP 
Methicillin-resistant strains (MRSP) were assessed by single PCR for 
mecA (Chovanovà et al., 2015) and mecC (Stegger et al., 2012) genes.  
S. aureus ATCC® BAA44TM was used as mecA positive control. 
Primers sequences, amplicon sizes and amplification programs are 
reported in Table 2.3. 
The single PCR reaction mixture for each gene (mecA and mecC genes) 
was prepared by using the Green Hot Start PCR Master Mix Direct 
Load, 2x (Biotechrabbit, GmbH, Germany) as follows: 
- Green Hot Start PCR Master Mix: 12,5 µL 
- primers (F+R): 1 µL 
- nuclease free water: 10,5 µL 
- DNA template: 1 µL 
The mixture final volume for one reaction was of 25 µL.  
For every PCR reaction there was always a positive and a negative 
control.  Genomic DNA was amplified using Biorad T100TM Thermo 
cycler (BioRad, Hercules, CA). 
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Tab. 2.3 Primers sequences, amplicon sizes, amplification programs of mec genes 
Gene Primer sequences  
(5’-3’ sense and antisense) 
Amplicon 
size (bp) 
Amplification 
program 
 
 
 
mecA 
 
 
 
 
 
 
mecC 
 
F: TCCACCCTCAAACAGGTGAA 
R: TGGAACTTGTTGAGCAGAGGT 
 
 
 
 
 
F: GAAAAAAAGGCTTAGAACGCCTC 
R: GAAGATCTTTTCCGTTTTCAGC 
 
139 
 
 
 
 
 
          
 
138 
 
94°C 5 min; 
94°C 30 s, 55°C 40s, 
72°C 30s,  
for 30 cycles; 
72°C 5 min. 
 
94°C 5 min; 
94°C 30s, 59°C 
60s,72°C 60s, 
for 30 cycles; 
72°C 10 min 
 
 
The amplified products were analyzed by gel electrophoresis and 
electrophoresed gels were visualized under blue-light and their images 
taken using the ChemiDocTM XRS+ with Image LabTM Software 
(BioRad, Hercules, CA), as previously described. 
 
2.2.2 Genotypic characterization of tetracycline and 
erythromycin resistance  
S. pseudintermedius strains showing phenotypic resistance to 
tetracycline were subjected to multiplex PCR to confirm, genotypically, 
the presence of the tetracycline resistance genes: tetK, tetM, tetL, tetO. 
Primers used for multiplex PCR were selected from primer sequences 
described by Ullah et al., (2012). The primer sequences used are shown 
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in Table 2.4. Moreover, single PCR were performed for each 
tetracycline resistance genes. 
According to literature in staphylococci of animal origin ermA, ermB 
and ermC have been identified as responsible for resistance to 
erythromycin (Zou et al., 2011). So, S. pseudintermedius isolates 
phenotypically erythromycin-resistant were analyzed with multiplex 
PCR to detect the presence of these three genes. Primers used (Table 
2.4) were chosen from published primer sequences (Sutcliffe et al., 
1996; Zou et al., 2011). Furthermore, single PCR were performed for 
each erythromycin resistance genes. 
 
The multiplex PCR reaction mixture for tetK, M, L, O genes was 
prepared by using the Green Hot Start PCR Master Mix Direct Load, 
2x (Biotechrabbit, GmbH, Germany) as follows: 
- Green Hot Start PCR Master Mix: 12,5 µL 
- primers tetK (F+R): 1 µL 
- primers tetM (F+R): 1 µL 4 µL 
-primers tetL (F+R):  1 µL 
- primers tetO (F+R): 1 µL  
- nuclease free water: 7,5 µL 
- DNA template: 1 µL 
The mixture final volume for one reaction was of 25 µL.  
 
The multiplex PCR reaction mixture for ermA, B, C genes was 
prepared by using the Green Hot Start PCR Master Mix Direct Load, 
2x (Biotechrabbit, GmbH, Germany) as follows: 
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- Green Hot Start PCR Master Mix: 12,5 µL 
- primers ermA (F+R): 1 µL 
- primers ermB (F+R): 1 µL 3 µL 
-primers  ermC (F+R): 1 µL 
- nuclease free water: 8,5 µL 
- DNA template: 1 µL 
The mixture final volume for one reaction was of 25 µL. 
For every multiplex PCR reaction there was always a positive and a 
negative control.  Genomic DNA was amplified using Biorad T100TM 
Thermo cycler (BioRad, Hercules, CA). 
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Tab. 2.4 Primers sequences, amplicon sizes, amplification programs of 
 tet and erm genes 
 
Gene Primers sequences 
(5’-3’ sense and antisense) 
Amplicon 
size (bp) 
Amplification 
programs 
tetK F: GTAGCGACAATAGGTAATAGT 
R: GTAGTGACAATAAACCTCCTA 
360 bp  
 
94°C 15s; 
94°C 1min, 52°C 
1min, 72°C 90s, 
for 30 cycles; 
72°C 5 min 
 
 
tetM F: AGTTTTAGCTCATGTTGATG 
R: TCCGACTATTTAGACGACGG 
1862 bp 
tetL F: ATAAATTGTTTCGGGTCGGTAAT 
R: AACCAGCCAACTAATGACAAGAT 
1077 bp 
tetO F: AACTTAGGCATTCTGGCTCAC 
R: TCCCACTGTTCCATATCGTCA 
515 bp 
ermA F: TCTAAAAGCATGTAAAAGAA 
R: CTTCGATAGTTTATTAATATTAGT 
645 bp  
94°C 2min; 
94°C 1min, 55°C 
1min, 72°C 90s, 
for 30 cycles; 
72°C 5 min 
 
ermB F: GAAAAGGTACTCAACCAAATA 
R: AGTAACGGTACTTAAATTGTTTAC 
639 bp 
ermC F: TCAAAACATAATATAGATAAA 
R: GCTAATATTGTTTAAATCGTCAAT 
642 bp 
 
The amplified products were analyzed by gel electrophoresis and 
Electrophoresed gels were visualized under blue-light and their images 
taken using the ChemiDocTM XRS+ with Image LabTM Software 
(BioRad, Hercules, CA), as previously described (Chapter 1). 
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3. Results 
 
3.1 Phenotypic and genotypic characterization of MRSP 
antibiotic resistance profiles  
Amongst the 126 S. pseudintermedius strains collected from dogs 
suffering from otitis externa or pyoderma during the years 2015-2017, 
23 strains (18%) were MRSP, being positive to mecA gene. The 
remaining 103 strains (82%) were classified as MSSP. None of the 
isolates carried mecC gene.  
The antimicrobial susceptibility results of the 23 MRSP, obtained by 
Kirby-Bauer disk diffusion testing on Mueller-Hinton agar (Liofilchem, 
Teramo, Italy), showed a complete resistance to amoxicillin-
clavulanate and ampicillin (100%), whilst the highest resistance rates to 
selected non-β-lactam antibiotics were: erythromycin (91%); 
tetracycline (87%); sulfamethoxazole/trimethoprim (78%); kanamycin 
(78%); streptomycin (78%); clindamycin (65%) and enrofloxacin 
(61%). However, no resistance was observed to vancomycin and 
linezolid. Furthermore, 91% (n=21) MRSP strains were found to be 
multidrug-resistant, showing resistance to at least 3 different antibiotic 
classes (Table 2.5).  
The 20 (87%) phenotypic tetracycline-resistant MRSP strains harbored 
tetK and tetM genes, alone or in association. Precisely, 2/20 (10%) 
tetracycline-resistant strains carried tetK and tetM together, 6/20 (30%) 
strains carried only tetK gene, while 12/20 (60%) harbored tetM gene 
alone.  
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Erythromycin resistance gene ermB was found positive in all the 21 
(91%) MRSP isolates, which were phenotypically erythromycin-
resistant. 
The distribution of tetK and tetM genes, ermB gene among MRSP and 
MSSP is described in Table 2.7. 
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Tab. 2.5 Antibiotic resistance profiles of canine MRSP 
MRSP Biolo- 
gical 
source 
 
A 
M 
C 
A 
M 
P 
F 
O 
X 
K 
F 
C 
R 
O 
C 
D 
C 
I 
P 
E 
N 
R 
E C 
N 
K I 
M 
I 
L 
N 
Z 
O 
X 
P S S 
X 
T 
T 
E 
T 
O 
B 
V 
A 
4 otitis 
externa 
R R R R R R S S R S R S S R R R R R S S 
22 otitis 
externa 
R R R R R S S R R R R R S R R R R R S S 
70 otitis 
externa 
R R R S R S S R R R S S S R R R R S S S 
75 pyoderma R R S S S S R R R S R S S R R R R R S S 
94 otitis 
externa 
R R R R R R R R R S R R S R R R R R S S 
102 otitis 
externa  
R R S R R R R R R R R R S R R R R R S S 
115 pyoderma R R R R R R R R R R R R S R R R R R R S 
147 otitis 
externa 
R R R S S R R R R S R R S R R R R R S S 
155 otitis 
externa 
R R R S S R R R R S R S S R R R S R S S 
166 otitis 
externa 
R R S S S S S S S R R S S R R R R R S S 
169 otitis 
externa 
R R R S S R R S R S R S S R R R S R S S 
171 pyoderma R R R R R R R R R R R R S R R R R R R S 
183 otitis 
externa 
R R R R R S R R R R S R S R R R R R S S 
184 pyoderma R R S S S S S S R S S R S R R S R S S S 
199 otitis 
externa 
R R R R R R S S R R R R S R R R R R S S 
218 otitis 
externa 
R R S S R R S R R R R R S R R R R R S S 
224 otitis 
externa 
R R S S S R S S R R R R S R R R S R S S 
227 otitis 
externa 
R R S S R R R R R R R R S R R R R R S S 
239 otitis 
externa 
R R S S S S S S R S S S S R R S S R S S 
246 otitis 
externa 
R R R S S S S S S S S S S R R S S R S S 
250 otitis 
externa 
R R R S S R R R R S R S S R R S R R S S 
251 otitis 
externa 
R R R S S R R R R S R S S R R S R R S S 
258 otitis 
externa 
R R S S S R S S R R R S S R R R R S R S 
N°R  23 23 14 8 11 15 12 14 21 12 18 12 0 23 23 18 18 20 3 0 
*R: resistant   **S: susceptible 
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 3.2 Phenotypic and genotypic characterization of MSSP antibiotic 
resistance profiles. 
The 103 MSSP (strains negative for both mecA and mecC genes) 
isolates, showed interesting antibiotic resistant profiles, but their 
resistance rates were of about 50% lower than MRSP strains to the 
same antibiotics, confirming the trends described worldwide. 
Precisely, the isolated MSSP showed, as predictable, high resistance 
rates to penicillin (77%), ampicillin (76%) and amoxicillin-clavulanate 
(56%). Among non-β-lactam antibiotics the most frequently found 
resistance phenotypes were tetracycline (50%), streptomycin (46%), 
kanamycin (44%), erythromycin (37%), sulfamethoxazole-
trimethoprim (35%).  Also, for MSSP no resistance was observed for 
vancomycin and linezolid.  Multidrug resistance was detected in 34% 
of MSSP (35/103) and the most prevalent association included 
amoxicillin-clavulanate, ampicillin, penicillin, tetracycline, 
erythromycin, kanamycin, streptomycin and sulfamethoxazole-
trimethoprim.  10% of MSSP isolates (11/103) were susceptible to all 
tested antibiotics.  
The resistance rates to the 20 tested antibiotics of both MRSP and 
MSSP are summarized in Table 2.6 and in Fig. 2.3. 
The 52 (50%) phenotypic tetracycline-resistant MSSP strains harbored 
tetK and tetM genes, alone or together. Precisely, 21% (11/52) of 
tetracycline-resistant MSSP carried tetK and tetM together, 33% 
(17/52) of the strains carried only tetK gene, while 46% (24/52) of 
MSSP isolates carried tetM gene alone.  
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The multiplex PCR for erm genes detected in 37% (38/103) phenotypic 
erythromycin-resistant MSSP the presence of ermB gene. 
The distribution of tetK, tetM, ermB genes among both MRSP and 
MSSP is reported in Table 2.7. 
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Tab. 2.6 Antibiotic resistance rates of MRSP and MSSP isolates of canine origin 
Antibiotics µg MRSP 
% resistance  
MSSP 
% resistance 
 Antibiotics by class 
 
Amoxicillin + 
clavulanate (AUG) 
 
30 
(20/10) 
 
100 
 
56 
 
Penicillin combination 
Ampicillin (AMP) 10 100 76 Penicillins 
Oxacillin (OX) 1 100 0 
Penicillin (P) 10 UI 100 77 
 
Cephalothin (KF) 30 35 6 Cephalosporins  
(first generation) 
Cefoxitin (FOX) 30 61 0 Cephalosporins 
 (second generation) 
Ceftriaxone (CRO) 30 48 12 Cephalosporins 
(third generation) 
Clindamycin (CD) 2 58 33 Lincosamides 
Ciprofloxacin (CIP) 30 52 9 Fluoroquinolones 
Enrofloxacin (ENR) 5 61 16 
Erythromycin (E) 15 91 37 Macrolides 
Gentamicin (CN) 10 52 10 Aminoglycosides 
Kanamycin (K) 30 78 44 
Streptomycin (S) 10 78 46 
Tobramycin (TOB) 10 13 4 
Imipenem (IMI) 10 52 36 Carbapenems 
Linezolid (LNZ) 30 0 0 Oxazolidinones 
Sulfamethoxazole-
Trimethoprim (SXT) 
25 
(1,25/23,75) 
78 35 Sulfonamides 
Tetracycline (TE) 30 87 50 Tetracyclines 
Vancomycin (VA) 30 0 0 Glycopeptides  
 
 
 
 
 
    
 
Antibiotic resistance in clinical S. pseudintermedius strains  
100 
 
Tab. 2.7 Molecular profiles of tetracycline and erythromycin resistance in canine 
S. pseudintermedius isolates 
 
Molecular profiles of tetracycline and 
erythromycin resistance  
 
MRSP 
(23 strains) 
MSSP 
(103 strains) 
  
tetK gene 
 
6 (26%) 
 
17 (16%) 
 tetM gene 12 (52%) 24 (23%) 
tetK and tetM genes 2 (9%) 11 (11%) 
 ermB gene 21 (91%) 38 (37%)  
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Fig. 2.3 Antibiotic resistance rates of MRSP and MSSP to the 20 tested antibiotics 
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4. Discussion and conclusions 
Antibiotic resistance is the most puzzling question in recent years and 
the spread of multidrug resistant Staphylococci of animal origin, 
principally MRSP strains, have assumed new public health relevance 
(Deurenberg et al., 2007; Corrente et al., 2013). This is due to their 
resistance not only to all β-lactams, but also to a wide range of other 
antibiotics with a limited susceptibility sometimes only to vancomycin 
and linezolid, considered as ‘last resort antibiotics’. In fact, their use in 
veterinary medicine appears questionable, since they are used for 
treatment of methicillin-resistant and multidrug-resistant staphylococci 
infections in human medicine (Stefani and Varaldo, 2003; Perreten et 
al., 2010; Vysakh and Jeya, 2013).  
In this context, the emergence in dogs of MRSP, often associated with 
even broader drug-resistance, has become a great veterinary challenge.  
This study confirms that S. pseudintermedius is the main causative 
staphylococcal agent of canine otitis externa and pyoderma. Precisely, 
among the 126 isolated S. pseudintermedius strains, 18% (23/126) were 
MRSP presenting almost all worrying multidrug-resistant profiles. 
Besides β-lactam antibiotics, the MDR profile of MRSP strains showed 
relevant resistance rates to all classes of antibiotics approved in 
veterinary medicine and used for systemic treatment in dogs 
(tetracycline, aminoglycosides, macrolides, sulfamethoxazole-
trimethoprim, lincosamides), confirming the multidrug resistance trend 
reported for MRSP worldwide (Osland et al., 2012; Haenni et al.; 
2014; Moodley et al., 2014; Stefanetti et al., 2017). 
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It is known that MRSP originates from an animal reservoir, 
consequently pet animals might act as potential reservoir for the 
emergence of novel methicillin-resistant clones in human beings.  Even 
though infection in humans with MRSP happens rarely, the potential 
transfer of antimicrobial resistance genes from MRSP to other 
staphylococci, such as S. aureus, might be possible. Furthermore, in 
last years it has been reported an increase of the zoonotic transmission 
of MRSP, probably due to a more appropriate identification of this 
strain, even though it still remains limited. The veterinary environments 
(hospitals, clinics) seem to play an important role in the dissemination 
of MRSP between pet animals and humans, particularly people who 
have a constant contact with pets (veterinary personnel and pet owners) 
(Paul et al., 2011; van Duijkeren et al., 2011). However, human 
colonization with MRSP appears to be unusual and transient, as 
reported for methicillin-susceptible S. intermedius. So human 
acquisition might be transiently related to increased colonization 
pressure or antibiotic exposure when they interact, especially for long 
time, with pets acutely ill (Wang et al., 2013). Veterinarians and 
owners of infected pets are exposed to a higher risk of being MRSP 
positive. Despite there are few reports of veterinarians, particularly pet 
animal dermatologists, colonized by MRSP, it could be considered as 
an occupational risk (Paul et al., 2011). 
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In this study, interesting antibiotic resistance profiles were also showed 
by MSSP isolated strains.  
Although their multiresistance pattern was lower than MRSP, the 
studied MSSP strains displayed a significant increasing trend of 
resistance compared to the data of some years ago (Ganiere et al., 2005; 
Norström et al., 2009). Moreover, the reported increasing trend is also 
confirmed by more recent studies of other European countries (Haenni 
et al. 2014; Moodley et al., 2014).  
The MSSP strains showed high resistance rates to antibiotics 
commonly used to treat canine infections, such as the penicillinase-
labile penicillins, tetracycline, aminoglycosides, macrolides and 
sulfamethoxazole-trimethoprim. It is worth noting that 34% of MSSP 
were multidrug-resistant strains (resistant to ≥ 3 different antibiotic 
classes), whilst only 10% of MSSP isolates were susceptible to all 
tested antibiotics.  
None of both MRSP and MSSP isolates showed resistance to 
vancomycin and linezolid, which use in veterinary medicine is disputed 
and in many authors’ opinion they should be strictly reserved for use in 
human beings, since they represent the last chance antibiotics to treat 
severe infections caused by methicillin-resistant staphylococci.  
Furthermore, in accordance with literature, this study shows that tetK 
and tetM genes were the most prevalent tetracycline resistance 
determinants in both MRSP and MSSP (Schmitz et al., 2001, Youn et 
al., 2014). Among the three macrolide resistance genes, all the 
erythromycin-resistant strains harbored only ermB gene, responsible 
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for erythromycin resistance in canine S. pseudintermedius strains 
(Boerlin et al., 2001; Lüthje and Schwarz, 2007; Youn et al., 2014). 
Even though MRSP are generally more resistant than MSSP and their 
high prevalence of multidrug resistance is probably related to the 
dissemination of dominant clones (for instance MRSP belonging to the 
clonal lineage ST71), according to literature the obtained results 
underline an increasing resistance in MSSP (Moodley et al., 2014). 
Therefore, the spread of multidrug-resistant MSSP should be monitored 
and their pathogenic role, related to antibiotic resistance, deserves 
further studies. 
Since the emergence and dissemination of methicillin-resistant 
staphylococci has posed a major challenge in the treatment of 
staphylococcal infections, when antibiotics are prescribed to small 
animals, it is important to remember that most of antibiotics are used 
also in human medicine, either as identical or related molecules, so they 
should be prescribed and administered wisely and whenever possible 
supported by antimicrobial susceptibility testing. Current EU Summary 
of Products Characteristics guidance for the responsible use of 
antimicrobials in veterinary medicine recommends a restricted use of 
fluoroquinolones, third-and fourth-generation cephalosporins to clinical 
cases always supported by antibiogram, because they are defined 
critically important antimicrobials by WHO (Pomba et al., 2017; 
Loeffler et al., 2018).  
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In conclusion, the increasing spread of multidrug-resistant MRSP and 
MSSP strains and the lack of effective, new, conventional antibiotics 
highlight the limited therapeutic possibilities and the need of new 
treatment approaches, such as antimicrobial peptides, to prevent and 
control staphylococcal infections.  
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Multilocus sequence typing for characterization of  
MRSP strains 
The discovery of new sequence types in Southern Italy 
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1. Introduction 
Multilocus sequence typing (MLST) is a nucleotide sequence-based 
method, which defines strains from the sequences of internal fragments 
of 7 housekeeping genes, in order to define a sequence type (ST) 
(Aanensen and Spratt, 2005). New sequence types are assigned when a 
new allelic profile is obtained. The 7 loci for S. pseudintermedius 
MLST are: tuf, cpn60 (hps60), pta, purA, fdh, ack, sar (Solyman et al., 
2013). The sequencing products (around 450-500 bp in size) are then 
analyzed thanks to the available database at the MLST Web-site 
(https://pubmlst.org/spseudintermedius/), in order to obtain an allele 
number for each gene. The combination of the seven allele numbers 
gives an allelic profile of the strains, defined sequence type (ST) 
(Aanensen and Spratt, 2005). Even though MLST is a very expensive 
technique, it is the best method for genetic screening (Deurenberg and 
Stobberingh, 2008) and for a reliable discrimination of clinical isolates 
of S. pseudintermedius, which has a considerable genetic diversity 
within the species (Fitzgerald, 2009). So, from this point of view, 
MLST appears to be the most effective method used to classify bacteria 
into clonal lineages and provide information about their relatedness, 
giving the possibility to define a specific bacterial population structure 
and its long-term epidemiological trends worldwide. Referring to the 
distribution of the main MRSP lineages, ST71, previously described as 
the epidemic European clone, is now widespread worldwide; while 
ST68, previously described as the epidemic North American clone, is 
now frequently reported also in Europe (Perreten et al., 2010) (Fig. 
3.1). Furthermore, ST45, ST258, ST261, ST112, ST265, ST169, ST181 
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clones have been reported in many countries (Pires dos Santos et al., 
2016). Recently, the newly ST497 and ST496, identified for the first 
time in Australia, have been reported (Worthing et al., 2018), 
confirming the high genetic variability of this species. 
The first species-specific MLST scheme was launched in 2013 
(Solyman et al., 2013), and its publicly available database 
(http://pubmlst.org/spseudintermedius/) contains records of 1173 
sequence types (STs) at present. Since 2007, numerous scientific papers 
have been reported MLST data on MRSP carriage and infection in a 
variety of countries and continents. 
Web of Science is searched systematically for articles reporting data on 
multilocus sequence typing (MLST) of S. pseudintermedius isolates 
from dogs or other animal or human patients and carriers. The results  
of this study regarding the finding of new clones have been added to 
data of the MLST database for this species.  
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Fig. 3.1  Population genetic structure of S. pseudintermedius lineage  
(Ruscher et al., 2010) 
On the top, the European endemic clone ST71. 
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2. Materials and Methods 
 
2.1 Multilocus sequence typing of MRSP isolates 
During 2015-2017, 126 clinical isolates of S. pseudintermedius were 
collected from two different cities of Southern Italy, Naples and Latina. 
The bacterial strains were obtained from dogs suffering from otitis 
externa and pyoderma.  
As reported in chapter 1, the identification of S. pseudintermedius 
strains was performed by MALDI-TOF MS and confirmed by single 
PCR for the species-specific nuc and hlb genes.   
 As already described in chapter 2, 18% (23/126) were MRSP strains, 
since harboured mecA gene, assessed by PCR. 
The genetic diversity of the 23 MRSP isolates was determined by 
multilocus sequence typing (MLST) of seven genes (tuf, cpn60, pta, 
purA, fdh, sar, and ack), as proposed by Solyman et al. (2013). MLST 
was performed in collaboration with Dr. Antonio Parisi at the Istituto 
Zooprofilattico Sperimentale di Puglia e Basilicata, Putignano-Bari, 
Italy.  
After bacterial DNA extraction by commercial kit as described in 
chapter 1, PCR were performed, and the amplicons were purified and 
subsequently sequenced.  
The primers sequences, previously employed by Soliman et al., (2013) 
and the amplicon sizes are reported in Table 3.1 
Alleles and sequence types (STs) were determined using the MLST 
database for S. pseudintermedius  
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(https://pubmlst.org/spseudintermedius/) and new sequence types were 
assigned by the curator Vincent Perreten.  
  
As described in chapter 2, the antibiotic resistance profiles of all 23 
MRSP isolates were evaluated by disk diffusion test on Mueller-Hinton 
agar plates. The following antibiotics were tested: amoxicillin-
clavulanate (AMC, 20/10 μg), ampicillin (AMP, 10 μg), oxacillin (OX, 
1 μg), penicillin (P, 10 IU), cephalothin (KF, 30 μg), cefoxitin (FOX, 
30 μg), ceftriaxone (CRO, 30 μg), clindamycin (CD, 2 μg), 
ciprofloxacin (CIP, 30 μg), enrofloxacin (ENR, 5 μg), erythromycin (E, 
15 μg), gentamicin (CN, 10 μg), kanamycin (K, 30 μg), streptomycin 
(S, 10 μg), tobramycin (TOB, 10 μg), imipenem (IMI, 10 μg), linezolid 
(LNZ, 30 μg), sulfamethoxazole-trimethoprim (SXT,1.25/23.75 μg), 
tetracycline (TE, 30 μg), vancomycin (VA, 30 μg) according to CLSI 
guidelines (2015), while breakpoints for streptomycin were the ones 
recommended by the French Society for Microbiology 
(http://www.sfm-microbiologie.fr).    
The 23 MRSP were also subjected to multiplex PCR (chapter 2) to 
determine genetic profiles of tetracycline (Ullah et al., 2012) and 
erythromycin resistance (Sutcliffe et al., 1996; Zou et al., 2011). 
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Tab. 3.1 Primers for MLST-7 of S. pseudintermedius and amplicon sizes 
Locus Primers sequences 
(5’-3’) sense and antisense 
Amplicon size 
(bp) 
 
 
tuf 
 
F: CAATGCCACAAACTCG 
R: GCTTCAGCGTAGTCTA 
 
500 
cpn60 F: GCGACTGTACTTGCACAAGCA 
R: AACTGCAACCGCTGTAAATG 
552 
pta F: GTGCGTATCGTATTACCAGAAGG 
R: GCAGAACCTTTTGTTGAGAAGC 
570 
purA F: GATTACTTCCAAGGTATGTTT 
R: TCGATAGAGTTAATAGATAAGTC 
490 
fdh F: TGCGATAACAGGATGTGCTT 
R: CTTCTCATGATTCACCGGC 
408 
ack F: CACCACTTCACAACCCAGCAAACT 
R: AACCTTCTAATACACGCGCACGCA 
680 
sar F: GGATTTAGTCCAGTTCAAAATTT 
R: GAACCATTCGCCCCATGAA 
521 
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3. Results 
 
3.1 MSRP clones 
The most frequently identified MRSP lineage in this study was ST71, 
with 6/23 strains (26%), whereas 2/23 (9%) strains were ST118, 2/23 
(9%) belonged to ST181 and one strain (4%) for each following STs: 
ST45, ST258, ST496, ST862 were identified.    
Herein, 9 new clones of MRSP out of 23 MRSP strains (39%) were 
found, as reported in Table 3.2. The newly described sequence types 
(STs) named from ST1053 up to ST1061, which were submitted and 
assigned by the curator of the PubMLST database, were for the first 
time reported in Italy and worldwide. 
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Tab. 3.2 Geographical, biological origin and clones of methicillin-resistant 
S. pseudintermedius 
 
Sample 
n. 
Animal 
host 
Biological 
source 
Geographical 
area 
Sequence types 
(STs) 
 
4 dog otitis externa Naples 118 
22 dog otitis externa Naples 71 
70 dog otitis externa Naples 71 
75 dog pyoderma Naples 1053 
94 dog otitis externa Naples 71 
102 dog otitis externa Naples 181 
115 dog pyoderma Naples 71 
147 dog otitis externa Latina 1054 
155 dog otitis externa Latina 1055 
166 dog otitis externa Naples 118 
169 dog otitis externa Latina 1056 
171 dog pyoderma Latina 71 
183 dog otitis externa Naples 71 
184 dog pyoderma Naples 496 
199 dog otitis externa Naples 45 
218 dog otitis externa Latina 862 
224 dog otitis externa Latina 1057 
227 dog otitis externa Naples 181 
239 dog otitis externa Latina 1058 
246 dog otitis externa Latina 1059 
250 dog otitis externa Naples 1060 
251 dog otitis externa Naples 1060 
258 dog otitis externa Naples 1061 
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The isolated MRSP strains showed interesting antibiotic resistance 
profiles (Table 3.3). In particular, most of them (91%) were multidrug-
resistant strains (resistant to at least 3 different antibiotic classes) and 
only the isolates belonging to the new STs 1058 and 1059 had a low 
degree of resistance. Moreover, only two ST71 strains, as well as two 
ST1060 strains, presented the same antibiotic resistance profiles. 
All 23 MRSP strains, analyzed by MLST, were resistant to amoxicillin-
clavulanate and ampicillin. High resistance rates were found for 
erythromycin (91%) and tetracycline (87%).  Interestingly, these clones 
were associated with carriage of the ermB gene and tetracycline 
resistance genes, precisely, tetM (60%) and tetK (30%) alone or 
together (10%). 
In addition, high percentages of resistance were the following: 
sulfamethoxazole/trimethoprim (78%); kanamycin (78%); streptomycin 
(78%); clindamycin (65%) and enrofloxacin (61%). However, no 
resistance was observed to vancomycin and linezolid.  
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Tab. 3.3 Origin, MLST analysis, phenotypic and genotypic antimicrobial resistance of 
MRSP isolates from canine cutaneous swabs 
 
MRSP 
origin 
STs Resistance phenotype  erm and tet 
genes  
Naples/otitis 
externa 
 
45 AMC, AMP, FOX, KF, CRO, CD, E, CN, K, IMI, OX, P, S, SXT, TE ermB, tetM 
Naples/otitis 
externa 
71 AMC, AMP, FOX, KF, CRO, ENR, E, CN, K, IMI, OX, P, S, SXT, TE ermB, tetK 
Naples/otitis 
externa 
71 AMC, AMP, FOX, CRO, ENR, E, CN, OX, P, S, SXT ermB 
Naples/otitis 
externa 
71 AMC, AMP, FOX, KF, CRO, CD, CIP, ENR, E, K, IMI, OX, P, S, SXT, 
TE 
ermB, tetM 
Naples/ 
pyoderma 
71 AMC, AMP, FOX, KF, CRO, CD, CIP, ENR, E, CN, K, IMI, OX, P, S, 
SXT, TE, TOB 
ermB, tetM 
Latina/ 
pyoderma 
71 AMC, AMP, FOX, KF, CRO, CD, CIP, ENR, E, CN, K, IMI, OX, P, S, 
SXT, TE, TOB 
ermB, tetM 
Naples/otitis 
externa 
71 AMC, AMP, FOX, KF, CRO, CIP, ENR, E, CN, IMI, OX, P, S, SXT, TE ermB, tetK 
Naples/otitis 
externa 
118 AMC, AMP, CN, K, OX, P, S, SXT, TE tetK 
Naples/otitis 
externa 
118 AMC, AMP, FOX, KF, CRO, CD, E, K, OX, P, S, SXT, TE ermB, tetK, 
tetM 
Naples/otitis 
externa 
181 AMC, AMP, KF, CRO, CD, CIP, ENR, E, CN, K, IMI, OX, P, S, SXT, TE ermB, tetM 
Naples/otitis 
externa 
181 AMC, AMP, CRO, CD, CIP, ENR, E, CN, K, IMI, OX, P, S, SXT, TE ermB, tetM, 
Naples/ 
pyoderma 
496 AMC, AMP, E, IMI, OX, P, SXT ermB 
Latina/otitis 
externa 
862 AMC, AMP, CRO, CD, ENR, E, CN, K, IMI, OX, P, S, SXT, TE, TOB ermB, tetM 
Naples/ 
pyoderma 
1053 AMC, AMP, CIP, ENR, E, K, OX, P, S, SXT, TE ermB, tetM 
Latina/otitis 
externa 
1054 AMC, AMP, FOX, CD, CIP, ENR, E, K, IMI, OX, P, S, SXT, TE ermB, tetK 
Latina/otitis 
externa 
1055 AMC, AMP, FOX, CD, CIP, ENR, E, K, OX, P, S, TE ermB, tetK 
Latina/otitis 
externa 
1056 AMC, AMP, FOX, CD, CIP, E, K, OX, P, S, TE ermB, tetK 
Latina/otitis 
externa 
1057 AMC, AMP, CD, E, CN, K, IMI, OX, P, S, TE ermB, tetK, 
tetM 
Latina/otitis 
externa 
1058 AMC, AMP, E, OX, P, TE ermB, tetM 
Latina/otitis 
externa 
1059 AMC, AMP, FOX, OX, P, TE tetM 
Naples/otitis 
externa 
1060 AMC, AMP, FOX, CD, CIP, ENR, E, K, OX, P, SXT, TE ermB, tetM 
Naples/otitis 
externa 
1060 AMC, AMP, FOX, CD, CIP, ENR, E, K, OX, P, SXT, TE ermB, tetM 
Naples/otitis 
externa 
1061 AMC, AMP, CD, E, CN, K, OX, P, S, SXT, TOB ermB 
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4. Discussion and conclusions 
In this study, MLST revealed 15 STs of which 9 were new clones. The 
most frequently isolated clone is represented by MRSP ST71, which is 
the largely predominant ST in Europe (Osland et al., 2012; Haenni et 
al., 2014; Damborg et al. 2016; Ventrella et al., 2017) and has diffused 
worldwide (Pires dos Santos et al., 2016). ST45, ST118, ST181, ST258 
were already reported in other countries, precisely ST 258 was 
described for the first time in Southern Italy by Ventrella et al. (2017). 
Referring to ST496, it was described only in Australia (Worthing et al., 
2018), so here is reported its first finding in Italy; as for the ST862 that 
was described only in USA, both cataloged in PubMLST.org. 
It is well known that MRSP are resistant to several non-β-lactam 
antibiotics (Ruscher et al., 2010; Perreten et al., 2010) and this was 
confirmed also by the results of this study, since the isolated MRSP 
clones exhibited interesting antibiotic resistance profiles, with high rate 
of resistance to non-β-lactam antibiotics. Precisely, in this study the 
isolates were almost all multidrug-resistant strains. In particular, MRSP 
strains belonging to ST71 clone were the most resistant, expressing 
worrying multidrug resistance patterns. These results, together with 
other reports, highlight the role of ST71 as a relevant pathogen not only 
for dogs, but also for other pets and humans, since infections by ST71 
have already been described in humans (Stegmann et al., 2010). 
Differently from ST71 clones, the isolates belonging to the new STs 
1058 and 1059 had a low degree of resistance. However, the strains of 
this study showed resistance to the classes of antibiotics commonly 
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used for systemic treatment in dogs. Moreover, none of the MRSP 
clones were resistant to vancomycin or linezolid, that in human 
medicine are considered as the ‘last resort antibiotic’ for treatment of 
infections caused by methicillin-resistant staphylococci.  
S. pseudintermedius propensity to horizontal transfer of resistance 
genes is considered one of the reasons for the rapid spread of 
multidrug-resistant strains (McCarthy et al., 2015; Pires dos Santos et 
al. 2016), displaying, thus, an epidemic population structure and a high 
genetic diversity.   
According to a recent multicenter study (Marques et al., 2016), MRSP 
and, in general, multidrug-resistant bacteria are more commonly 
disseminated in Southern Europe than in Northern Europe. This seems 
to be a consequence of the lack of national antibiotic usage guidelines 
and surveillance programs in Southern European countries. So, 
surveillance initiatives in pet animals would be useful in order to obtain 
data on antibiotic resistance patterns of pet pathogens, with particular 
attention for those showing multidrug-resistant phenotypes and 
zoonotic potential, such as S. pseudintermedius.  
In conclusion, the results of this study demonstrated the circulation of 
different and new MRSP lineages from clinically diseased dogs in 
Southern Italy. Considering that few information on genetic lineages 
and clonal spread of MRSP are currently available, these findings 
justify the need of a constant epidemiological monitoring of MRSP.  
Moreover, according to literature, some clones isolated in this study 
have been already detected both in pets and humans, so an increased 
surveillance should be addressed with a One Health approach. 
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DIBI and abietic acid antimicrobial activity against S. pseudintermedius 
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1. Introduction 
Widespread emergence of multidrug-resistant bacterial pathogens is a 
problem of global dimension. And multidrug-resistant MRSP and 
MSSP strains represent an important problem to animal health and an 
increasing therapeutic challenge in veterinary medicine. The regulatory 
pressure to limit antibiotic use and the everincreasing incidence of 
multidrug-resistant bacterial strains among companion animals with 
otitis externa, pyoderma and other infections create a need for new 
treatment approaches.  
Among new therapeutic strategies, there is the one based on the 
combination antibiotic therapy which is practiced for different reasons 
such as broadening antibacterial spectrum, polymicrobial infection 
treatment and overall for its synergistic action. 
Another strategy could be the use of adjuvants able to act in concert 
with the known conventional antibiotics, thus enhancing their activity, 
especially against resistant isolates.  
A non-antibiotic treatment approach has particular interest as do agents 
that can improve response to conventionally used antibiotics. 
Alternative treatments for bacterial infections as phage therapy, use of 
probiotics and prebiotics, antibacterial peptides, nanoparticles and so 
on, represent noteworthy ongoing developments in the field of 
antibacterials. 
Alternative non-antibiotic treatment strategies need to be explored to 
ensure that a robust pipeline of effective therapies is available to both 
human and veterinary medicine (Ruiz et al., 2017).  
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In this study the antibacterial activity of two different agents, 
hydroxypiridone-based iron chelating co-polymer DIBI and abietic 
acid, against MRSP and MSSP was evaluated. Moreover, the 
synergistic interaction between these agents and specific antibiotics was 
also investigated.  
 
DIBI, a novel water-soluble hydroxypyridinone-containing iron 
chelating polymer, developed by Chelation Partners Inc. (Canada), 
provides a potential new antibacterial treatment by denying pathogens 
of iron as needed for their growth (Fig. 4.1.).   
 
 
Fig. 4.1 DIBI 
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Previous minimum inhibitory concentration (MIC) studies has already 
shown that DIBI is effective against representative reference strains for 
Gram-positive and Gram-negative bacteria Staphylococcus aureus and 
Acinetobacter baumannii, and the yeast Candida albicans and 
Malassezia pachydermatis (Ang et al., 2018; Del Carmen Parquet et 
al., 2018; Savage et al., 2018). All pathogens implicated in otitis (and 
all other non-viral infectious agents) require iron to grow and to infect 
their host, in fact the animal host already attempts to limit infection 
through active partial iron sequestration, i.e, as part of the innate 
immune response, early in infections when microbial iron requirements 
are highest.  
DIBI has been conceived to bolster the existing innate iron related host 
defenses and has already been shown to be non-toxic when 
administrated at repeated high dosage to the ear canal of healthy dogs 
(Kingfisher 2017).                                            
 
Abietic acid, extracted from tree rosin, contains both a conjugated 
diene and a carboxylic acid, both of which are readily reacted on a 
commercial scale. The resin of pine trees (Pinus sp.) is the main source 
of abietic acid, which can be also obtained from many other coniferous 
trees. In the past, natural products from plants, fungi and bacteria have 
been successfully used for their antimicrobial activity. Pine resin has 
been used for several millennia to treat external skin conditions 
including wounds, boils and pyodermas (San Feliciano et al., 1993).  
Precisely, abietic acid is a diterpenoid that vaunts a well-studied 
bioactivity profile, including antiviral, antibiotic and antifungal activity 
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(Fig. 4.2). In particular, abietic acid has shown an intrinsic activity 
mainly against Gram-positive bacteria, such as Staphylococcus aureus, 
and yeasts (Gigante et al., 2003; Gu et al., 2010; Caetano da Silva et 
al., 2014; Leandro et al., 2014).  
 
 
 
Fig. 4.2 Abietic acid 
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2. Materials and Methods 
 
2.1 In vitro sensitivity of clinical canine S. pseudintermedius isolates 
to DIBI 
DIBI, a novel water-soluble hydroxypyridinone-containing iron 
chelating polymer, developed by Chelation Partners Inc. (Canada), was 
tested against 5 S. pseudintermedius strains isolated from dogs 
suffering from otitis externa. As reported in chapter 1, the identification 
of S. pseudintermedius strains was performed by MALDI-TOF MS and 
confirmed by single PCR for the species-specific nuc and hlb genes.  
Among these strains, one was a methicillin-resistant S. 
pseudintermedius (MRSP) strain and four were methicillin-susceptible 
S. pseudintermedius (MSSP) strains, as confirmed by mecA gene PCR, 
reported in chapter 2.  Moreover, these strains showed resistance 
profiles to antibiotics that are frequently prescribed to dogs for MRSP 
or MSSP infections (Table 4.1). 
The antimicrobial DIBI activity was tested in collaboration with Dr. 
Maria Del Carmen Parquet and Dr. Bruce Holbein, Chelation Partners 
Inc., 1411 Oxford St., Halifax, NS, B3H 3Z1 Canada. 
 
2.1.1 Bacterial cultivation  
S. pseudintermedius strains were routinely cultured from glycerol 
frozen stocks (-80 °C) and maintained on Trypticase Soy Agar (TSA). 
To test DIBI activity, liquid cultures were grown in Roswell Park 
Memorial Institute Medium 1640 (RPMI, Sigma-Aldrich) 
supplemented with 2% (w/v) glucose, buffered with 0.165 M 3-(N-
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morpholino)-propanesulfonic acid (MOPS) for 18-24 h at 37 °C with 
shaking. RPMI medium was chosen for this study because it contains a 
relatively low but yet sufficient iron content (approx 0.1 µM Fe) and 
this therefore better emulate in vivo iron availability conditions. RPMI 
grown cultures were used to prepare inocula for MIC determinations.  
 
2.1.2 Susceptibility testing 
DIBI stocks were prepared in RPMI (200 mg/mL). All stocks solutions 
were filter-sterilized (0.2 µm filter) before use. Differently from 
antibiotics, DIBI interrupts microbial iron supply and therefore it 
affects many iron-dependent targets at the level of DNA, protein and 
lipid synthesis as well as for energy production and defense. 
MIC determinations were determined using the broth microdiluition 
method (EUCAST, 2017), in 96-well round-bottomed plates (Life 
Sciences). As a general rule, RPMI was the assay medium and diluent 
for testing S. pseudintermedius strains.  
 
The MIC for DIBI was determined and for this, DIBI was diluted in 
RPMI with serial 1/2 dilutions made covering the ranges 0.06-128 
µg/mL.  To prepare the serially diluted 96 well plates, RPMI was added 
first to each well. Next, a similar volume of DIBI at a concentration 
equal to twice the highest concentration (2X) desired was added to the 
well. Then, the contents of this wells were mixed and serially diluted 
across the row to achieve the dilution series. 
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For inoculum preparation, RPMI overnight cultures were diluted in 
their respective fresh media to an optical density (OD 600 nm) of 0.1 
and MIC plates were inoculated to a final dilution of 1/200. Negative 
and positive controls were included in parallel. All MIC plates were 
incubated at 35°C for 24-72 h and then read as to MIC. MIC value was 
defined as the lowest concentration of chelator required to inhibit 
visible growth at 24 h incubation. 
 
2.2 Antimicrobial properties of abietic acid against clinical canine 
S. pseudintermedius strains 
Abietic acid (75%) used in this study was purchased commercially 
(Alfa Aesar, Ward Hill, Massachusetts, USA) and there was no need of 
a further purification for its use. Abietic acid was only dissolved in 
ethanol and diluted in TSB broth to obtain a stock solution. 
Abietic acid was tested against 2 clinical canine otitis S. 
pseudintermedius isolates. As described in chapter 1, the identification 
of S. pseudintermedius strains was performed by MALDI-TOF MS and 
confirmed by single PCR for the species-specific nuc and hlb genes. 
Furthermore, mecA gene was detected by PCR (chapter 2) revealing 
one methicillin-resistant S. pseudintermedius (MRSP) strain and one 
methicillin-susceptible S. pseudintermedius (MSSP) strain. These 
strains showed also interesting resistance profiles (Table 4.2). 
The antimicrobial abietic acid activity was evaluated in collaboration 
with the Department of Molecular Medicine and Medical 
Biotechnology and the Department of Pharmacy, University of Naples 
“Federico II”, Italy.  
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2.2.1 S. pseudintermedius cultivation and susceptibility testing 
In order to evaluate acid abietic antimicrobial activity, two S. 
pseudintermedius isolated strains were plated again on blood agar base 
supplemented with 5% sheep blood and on Mannitol Salt agar (MSA), 
and incubated aerobically at 37 °C for 24–48 h.  
Minimal inhibitory concentrations (MIC) of abietic acid was 
determined in TSB medium by the broth microdilution assay, according 
to the European Committee on Antimicrobial Susceptibility Testing 
(2017). Bacterial suspensions were diluted to yield an OD around 0.5 at 
595 nm and further diluted to a final concentration of 1 × 106 CFU/mL. 
The compounds were added to bacterial suspension in each well 
yielding a final cell concentration of 5 × 105 CFU/mL and a final 
compound concentration ranging from 2 to 128 μg/mL. Negative 
control wells were set to contain bacteria in TSB plus the amount of 
ethanol used to dilute each compound. Positive controls included 
oxacillin (2 μg/mL) and vancomycin (2 μg/mL). Medium turbidity was 
measured by a microtiter plate reader (Tecan, Milan, Italy) at 595 nm. 
Absorbance was proportional to bacterial growth. Minimum 
bactericidal concentration (MBC) was defined as the concentration that 
caused ≥ 3log10 reduction in colony count from the starting inoculum 
plated on TSA, incubated for 24 h at 37 °C. 
 
2.2.2 Killing rate and checkerboard method 
Time kill assay was carried out as previously described in Olajuyigbe et 
al. (2012) with minor modifications. Bacterial suspension (105 
CFU/mL) was added to microplates along with abietic acid at the MIC 
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concentrations (8 μg/mL and 32 μg/mL). Plates were incubated at 37 
°C on an orbital shaker at 120 rpm. Viability assessments were 
performed at 0, 2, 4, 6, and 24 h by plating 0.1 mL undiluted and 10-
fold serially diluted samples onto LB plates in triplicate. After the 
overnight incubation at 37 °C, bacterial colonies were counted and 
compared with counts from control cultures. 
 
The interaction between abietic acid and oxacillin against MRSP was 
evaluated by the checkerboard method in 96-well microtiter plates 
containing TSB. Briefly, abietic acid and oxacillin were serially diluted 
along the y and x axes, respectively. The final antimicrobial substance 
concentrations (after two-fold dilution) ranged from 1/16 to 1 times the 
MIC for oxacillin and from 1/64 to 1 times the MIC for abietic acid. 
The checkerboard plates were inoculated with bacteria at an 
approximate concentration of 105 × CFU/mL and incubated at 37°C for 
24 h, following which bacterial growth was assessed visually and the 
turbidity measured by microplate reader at 595 nm. To evaluate the 
effect of the combination treatment, the fractional inhibitory 
concentration (FIC) index for each combination was calculated as 
follows: FIC index = FIC of abietic acid + FIC of oxacillin, where FIC 
of abietic acid (or oxacillin) was defined as the ratio of MIC of abietic 
acid (or oxacillin) in combination and MIC of abietic acid (or oxacillin) 
alone. The FIC index values were interpreted as follows: ≤0.5, 
synergistic; >0.5 to ≤1.0, additive; >1.0 to ≤2.0, indifferent; and >2.0, 
antagonistic effects (Pillai et al., 2005). 
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3. Results 
 
3.1 Susceptibility of S. pseudintermedius isolates to DIBI  
All S. pseudintermedius strains displayed high sensitivities to DIBI 
with a MIC of 2 µg/mL at 24 h (Table 4.1). Furthermore, DIBI 
sensitivity was not linked to antibiotic sensitivity or resistance of the 
strains. 
 
Tab. 4.1 Antibiotic resistance, methicillin resistance profiles, DIBI antimicrobial 
activity in 5 clinical canine otitis S. pseudintermedius isolates. 
 
Sample 
n. 
Key antibiotic resistance mecA gene 
detection 
DIBI 
MIC 
µg/mL 
 
3 
 
AMC, AMP, CD E, K, P, S, SXT, TE 
 
- 
 
2 
4 AMC, AMP, FOX, KF, CRO, CD, E, K, OX, 
P, S, SXT, TE 
+ 2 
7 AMC, AMP, E, CN, K, P, S, SXT, TE, TOB - 2 
8 AMC, AMP, P, SXT, TE - 2 
18 AMC, AMP, E, K, IMI, P, S, TE - 2 
 
 
3.2  In vitro abietic acid antimicrobial activity 
 
The antimicrobial activity of abietic acid against MRSP and MSSP 
strains was evaluated. Antibiotic resistance patterns of both strains are 
reported in Table 4.2, whereas MIC values are shown in table 4.3. 
Abietic acid exhibited a significant MIC90 value at 32 μg/mL (MRPS) 
and 8 μg/mL (MSSP), while MBC values were 64 μg/mL (2X MIC) 
and 32 μg/mL (4X MIC) against MRSP and MSSP strains, 
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respectively. The MBC/MIC ratio or MICindex was also calculated. 
When the ratio of MBC/MIC was ≤ 2.0, the extract was considered 
bactericidal or otherwise bacteriostatic. The results in Table 4.3 showed 
a bacteriostatic activity against MSSP (MICindex 4), while the result 
about the MRSP has been further investigated. The time-kill assay 
results, presented in terms of the changes in the log10 CFU/mL of viable 
colonies, confirmed the bacteriostatic activity of abietic acid (Table 
4.4) against both S. pseudintermedius strains.  Abietic acid was able to 
inhibit bacterial growth already at 1 h, with a percentage of CFU 
reduction of 60% and 30% for MSSP and MRSP, respectively, 
compared to untreated bacteria. The highest inhibition activity of 
abietic acid was observed after 6 h exposure with a percentage 
reduction of 90% and 75% for MSSP and MRSP, respectively. 
However, after 24 h a cell growth resumption was observed in abietic 
acid-treated strains, even though not comparable to untreated cells 
(<3log10). Thus, the bacteriostatic effect of abietic acid on both S. 
pseudintermedius strains was confirmed.  
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Tab. 4.2 Antibiotic resistance and methicillin resistance profile in 2 clinical canine otitis 
S. pseudintermedius strains 
 
Sample n.  Key antibiotic resistance mecA gene 
detection 
 
21 
 
AMC, AMP, IMI, P, TE 
 
- 
22 AMC, AMP, FOX, KF, CRO, ENR, E, CN, K, 
IMI, OX, P, S, SXT, TE 
 
+ 
 
 
Tab. 4.3 MIC90, MBC, MICindex, FICindexvalues of abietic acid on selected 
S. pseudintermedius strains 
 
Strains MIC 
(g/mL) 
MBC 
(g/mL) 
Oxacillin 
(g/mL) 
Vancomycin 
(g/mL) 
MICindex FICindex 
 
MSSP 
 
8 
 
32 
 
<0,25 
 
2 
 
4 
 
n.d.* 
MRSP 32 64 10 2 2 0,375 
*  N.d.= not determined. Each experiment is the result of three independent experiments 
performed in triplicate. 
 
 
Tab. 4.4 Time-kill assay of abietic acid against MSSP and MRSP 
Strains   Log10CFU/mL      
  0h 1h 2h 4h 6h 24h 
 
MSSP untreated 
 
5,60 
 
5,84 
 
5,90 
 
5,97 
 
7,30 
 
9,77 
MSSP + abietic acid 5,50 3,20 2,60 2 1,60 6,97 
MRSP untreated 5,30 5,47 5,74 5,81 6,91 8,36 
MRSP + abietic acid 5,40 3,77 3,38 2,30 1,77 5,86 
 
* Each experiment is the result of three independent experiments performed in triplicate. 
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3.3 Synergistic assay of abietic acid with oxacillin against MRSP 
The synergism between abietic acid and oxacillin was determined using 
the checkerboard technique. Oxacillin and abietic acid were tested 
alone and in combination against MRSP planktonic cells. The drugs 
concentrations decreased along the rows and column from 32 μg/mL to 
0 μg/mL (abietic acid) and 10 μg/mL to 0 μg/mL (oxacillin). The 
highest synergistic interaction against MRSP was obtained in the wells 
with the best combination values of 4 μg/mL abietic acid (1/8 MIC) and 
2,5 μg/mL oxacillin (1/4 MIC). The FIC index, equal to 0.375, 
confirmed the synergistic effect of abietic acid and oxacillin (Table 
4.3). 
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4. Discussion and conclusions 
Antibiotic resistance is one of the most urgent threats to the public's 
health and the increasingly limiting therapeutic options both in human 
and veterinary medicine underline the need of alternative treatments. 
Since the lack of effective antibiotics in veterinary field and the 
increase of zoonotic transmission are becoming a looming scenery, the 
antimicrobial properties of DIBI (a proprietary iron chelator of 
Chelation Partners Inc.) and abietic acid were here investigated.   
 
In this study, DIBI resulted to be effective against MRSP and MSSP 
strains, inhibiting their growth at a MIC value of 2 µg/mL.  This 
investigation has also shown that DIBI had stand-alone as an 
alternative anti-infective potential as a “non-antibiotic” anti-infective 
for treating otitis caused by S. pseudintermedius strains.  The obtained 
results provided evidence that the new, highly water-soluble, low 
molecular weight co-polymer DIBI, depriving microorganisms of 
bioavailable iron, may represent a promising strategy for new anti-
infective agents. In fact, it was proved that the novel chelator DIBI 
could restrict growth and also enhance the activity of antimicrobial 
agents against clinical bacterial and fungal isolates (Savage et al., 
2018). An iron chelator, such as DIBI, offers potential broad utility as 
an alternative anti-infective for treating staphylococcal infections in 
man and other animals. Recently, Del Carmen Parquet et al. (2018) 
demonstrated that DIBI was found to be strongly inhibitory to a diverse 
group of S. aureus isolates regardless of their animal origin (human, 
cattle or dogs) and irrespective of their antibiotic resistance 
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characteristics. Thus, DIBI has potential as a non-antibiotic alternative 
therapy. 
 
Abietic acid and its derived compounds are known for their 
antibacterial activity (Helfenstein et al., 2017). In this study, abietic 
acid strongly reduced both MSSP and MRSP growth (MIC90) showing 
a bacteriostatic activity in the first hours of treatment. Bacterial growth 
was inhibited already after 1 h, reaching the peak after 6 h of exposure. 
Interesting, the MIC values here reported were lower than those 
observed in a study on S. aureus by Helfenstein et al. (2017). 
At the MBC concentration (32 and 64 μg/mL for MSSP and MRSP, 
respectively) bacterial cell death was observed. The abietic acid activity 
here observed might be attributable to the carboxylic group, which 
interacts with the lipid component of the bacterial cellular membrane 
and allows the penetration of the molecule inside the membrane, 
altering its functions (Aranda et al., 1997; Cuzzucoli Crucitti et al., 
2018). Worthy of note, abietic acid presented good biocompatibility as 
assessed by hemolytic assay, demonstrating a negligible lytic activity, 
and it was no toxic against human normal fibroblast (Sadashiva et al., 
2015; Cuzzucoli Crucitti et al., 2018).  The synergistic interaction 
between abietic acid and oxacillin highlighted a relevant result, since 
abietic acid was able to increase oxacillin sensibility of MRSP.  
Taking everything into account, there is currently no certain indication 
that MRSP is more virulent than MSSP, since both MRSP and MSSP 
show an increased resistance to most of all antibiotics licensed for use 
in pets. The results reported above, suggest that DIBI and abietic acid 
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may be considered potential therapeutic agents to be used alone or in 
combinatorial antibiotic therapy, particularly useful to treat infections 
caused by multidrug-resistant strains, that are becoming more and more 
difficult to manage. Awareness, current research and comprehensive 
management of infections are required by veterinarians not only to 
support treat infected companion animals but also to limit the spread 
and prevent the establishment of this highly drug‐resistant and zoonotic 
pathogen in veterinary facilities and in the community. 
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